In vivo role of high-affinity immunoglobulin E receptors on dendritic cells by Mitterhumer, Eva
  
 
 
 
 
 
 
 
 
 
DISSERTATION 
 
 
 
 
Titel der Dissertation 
 
 
 
In vivo role of high-affinity immunoglobulin E receptors on  
dendritic cells 
 
 
 
 
 
angestrebter akademischer Grad 
 
Doktor/in der Naturwissenschaften (Dr. rer. nat.) 
 
 
 
 
 
 
 
Verfasserin / Verfasser: Mag.a Eva Mitterhumer 
Matrikel-Nummer: 9820440 
Dissertationsgebiet (lt. 
Studienblatt): 
441 Genetik - Mikrobiologie 
Betreuerin / Betreuer: Univ.-Prof. Dr. Dieter Maurer 
 
 
 
 
Wien, am 25. Juni 2009 
 
 
Mitterhumer Eva                    Abstract 
 
 3 
Abstract 
 
 
Type 1 allergy, in particular allergic asthma, is a severe inflammatory disease of 
high socioeconomic importance. Pathophysiologically, type 1 allergic responses 
consist of an early (EAR) and a late-phase allergic reaction (LAR). The short-
lived EAR is initiated by allergen-dependent crosslinking of mast cell-expressed 
high-affinity IgE receptors (FcεRI). The LAR, in contrast, persists for hours to 
days and is independent of mast cell activation but depends on tissue infiltration 
with allergen-specific Th2 lymphocytes, dendritic cells (DCs), and eosinophils. 
Eosinophils release soluble mediators of tissue damage and, thus, are the main 
effector cells of LARs. In human allergic asthma, LAR-associated inflammation 
is the main cause for ventilatory insufficiency. Frequent occurrence of severe 
LARs can promote chronic asthma and irreversible fibrotic lung remodelling. As 
the consequence, the LAR, even more the EAR, is the main reason of morbidity 
and mortality in human type 1 allergy.  
Besides its presence on mast cells, FcεRI is also expressed on human 
antigen-presenting cells such as DCs in various tissues like the lung. In vitro 
studies demonstrated that IgE bound to FcεRI on DCs increases antigen 
uptake, processing and peptide presentation to CD4+ T helper (Th) 
lymphocytes. Accordingly, it can be speculated that DC-expressed FcεRI 
contributes to the induction and the severity of LARs in vivo. However, the in 
vivo relevance of FcεRI on DCs remained enigmatic due to the lack of suitable 
animal models. Mice, for instance, express FcεRI on mast cells and basophils 
but, unlike humans, lack FcεRI expression on any type of their antigen-
presenting cells. 
In order to study the in vivo role of DC-expressed FcεRI for T cell 
activation and its contribution to allergic inflammation, we generated transgenic 
mice which display a “human-like” expression pattern of FcεRI. These α-DC TG 
mice express the IgE binding α-chain of human FcεRI and green fluorescent 
protein under the control of the murine DC-specific CD11c promoter. α-DC TG 
mice allowed us to demonstrate that FcεRI on DCs is an efficient inducer of Th2 
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cell development and a critical amplifier of the Th2-dependent LAR in the lung. 
In the presence of allergen and IgE, the FcεRI+ DCs instructed naïve T cells to 
differentiate into Th2 cells leading to augmented allergen-specific Th2 
responses in vivo. Eosinophils, the main inflammatory effector cells in the LAR, 
were attracted into the lungs as dependent on IgE and the expression of FcεRI 
by DCs. This recruitment was mediated by the enhanced expression of 
eosinophil chemoattractants in the lungs of α-DC TG mice. Thus, FcεRI on DCs 
initiates the cascade of those immunologic events which result in cell-
dependent late-phase allergic tissue inflammation.  
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Zusammenfassung 
 
 
Die Typ 1 Allergie, im Besonderen allergisches Asthma, ist eine 
schwerwiegende entzündliche Erkrankung von großer sozioökonomischer 
Bedeutung. Pathophysiologisch gesehen, setzt sich die Typ 1 allergische 
Reaktion aus einer Früh- (early-phase allergic reaction, EAR) und einer 
Spätphasenkomponente (late-phase allergic reaction, LAR) zusammen. Die nur 
kurz andauernde EAR wird durch die Allergen-abhängige Vernetzung des auf 
Mastzellen exprimierten hochaffinen IgE Rezeptors (FcεRI) initiiert. Im 
Gegensatz dazu besteht die LAR für Stunden bis zu Tagen und ist nicht von 
Mastzellaktivierung abhängig, beruht jedoch auf der Infiltration des Gewebes 
mit Allergen-spezifischen Th2 Lymphozyten, dendritischen Zellen (DZ) und 
eosinophilen Granulozyten. Eosinophile Granulozyten setzen lösliche 
Mediatoren zur Schädigung des Gewebes frei und sind demzufolge die 
Haupteffektorzellen der LAR. Beim allergischen Asthma des Menschen ist die 
LAR-assoziierte Inflammation die Hauptursache für die krankheitstypische 
Atmungsinsuffizienz. Häufiges Auftreten von schweren LARs kann zur 
irreversiblen fibrotischen Remodellierung der Lungenstruktur und damit zu 
persistierender restriktiver Lungenfunktionsschädigung führen. Folglich ist die 
LAR mehr noch als die EAR die Hauptursache für Morbidität und Mortalität der 
Typ 1 Allergie beim Menschen.  
Neben seiner Präsenz auf Mastzellen ist FcεRI auch auf humanen 
Antigen-präsentierenden Zellen wie auf DZ in verschieden Geweben wie der 
Lunge exprimert. In vitro Studien zeigten, dass IgE, gebunden an FcεRI auf DZ, 
die Antigenaufnahme, Prozessierung und Peptidpräsentation an CD4+ Helfer 
T(Th)-Zellen erhöht. Dementsprechend kann man vermuten, dass dem auf DZ 
exprimierten FcεRI eine Bedeutung in der Induktion und der Regulation des 
Schweregrads der Th2 Zell-abhängigen LAR in vivo zukommt. Die in vivo 
Relevanz des von DZ exprimierten FcεRI blieb jedoch aufgrund des Fehlens 
von geeigneten Tiermodellen unklar. Mäuse exprimieren FcεRI auf Mastzellen 
und basophilen Granulozyten, aber anders als im Menschen, fehlt ihnen die 
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FcεRI-Expression auf Antigen-präsentierenden Zellen.  
Um die in vivo Rolle des von DZ exprimierten FcεRI für die T-Zell-
Aktivierung und seine Rolle in der allergischen Entzündung zu untersuchen, 
entwickelten wir ein transgenes Mausmodell, welches das „humane“ 
Expressionsmuster von FcεRI simuliert. Diese α-DC TG Maus exprimiert die 
IgE-bindende α-Kette des humanen FcεRI und ein grün fluoreszierendes 
Protein unter dem für murine DZs spezifischen CD11c Promotor. Mit Hilfe 
dieser α-DC TG Mäuse konnten wir zeigen, dass FcεRI auf DZs ein effizienter 
Auslöser einer Th2 Zellentwicklung und ein entscheidender Verstärker der Th2-
abhängigen allergischen Entzündung ist. In Anwesenheit eines Allergens und 
IgE, instruierten FcεRI+ DCs naive Th Zellen in Th2 Zellen zu differenzieren, 
was in einer verstärkten Allergen-spezifischen Th2 Antwort in vivo resultierte. 
Eosinophile Granulozyten, die Haupteffektorzellen der LAR, wurden IgE- und 
FcεRI-abhängig in die Lunge rekrutiert. Diese Rekrutierung wurde durch die 
vermehrte Expression von Chemoattraktantien für eosinophile Granulozyten in 
den Lungen von α-DC TG Mäusen vermittelt. Demzufolge schließen wir, dass 
FcεRI auf DZs die Kaskade von immunologischen Prozessen initiiert, welche 
die Spätphase der allergischen Gewebsentzündung bewirken. 
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List of Abbreviations 
 
 
Ab antibody 
AD atopic dermatitis 
Ag antigen 
APC (1) antigen-presenting cell 
 (2) allophycocyanin 
biot biotinylated  
BSA bovine serum albumine 
CHO Chinese hamster ovary 
CaCl2 calcium chloride 
CD cluster of differentiation 
CD40L  CD40 ligand 
CFSE Carboxyfluorescein succinimidyl ester 
DC dendritic cell 
DDC interstitial (dermal) DCs  
DMF dimethylformamide 
DTH delayed-type hypersensitivity reactions 
EAR early-phase of allergic reaction 
EC50 effective concentration50 
eGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
eos eosinophil 
EtOH ethanol 
Fab antigen-binding fragment 
FACS fluorescence-activated cell sorting 
Fc Fragment, crystalline; receptor binding site 
FcεRI high-affinity IgE receptor 
FcεRIα alpha-chain of the high-affinity IgE receptor 
FcεRIβ beta-chain of the high-affinity IgE receptor 
FcεRIγ gamma-chain of the high-affinity IgE receptor 
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FcεRII low affinity IgE-receptor 
FcγR receptors for IgG 
ER endoplasmic reticulum 
FCS fetal calf serum 
FITC fluoresceinisothiocyanate 
GAB2 growth-factor receptor-bound protein 2 –associated 
 binding protein 2 
h hour(s) 
HEPES (N-[2-hydroxyethyl]piperazin-N´-[2-ethane sulfonic acid]) 
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IFN interferon 
IFNAR IFN-α receptor 
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IL interleukin 
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IMDM Iscove´s modified Dulbecco´s medium 
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i.v. intravenously  
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MΦ macrophage 
mAb(s) monoclonal antibody (-ies) 
MACS magnet-activated cell sorting 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
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min minute(s) 
mg milligram 
ml milliliter 
mM millimolar 
NP 4-Hydroxy-3-nitrophenylacetyl 
nTreg naturally occurring regulatory T cell 
ON over night 
Ova ovalbumin 
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pCD11c CD11c promoter 
PE phycoerythrin 
PerCP peridinin chlorophyll protein 
pH negative decadic logarithm of hydrogen ion concentration 
 ([H+]) 
PI3K  phosphatidylinositol 3-kinase 
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RAG2 recombination-activating gene 2 
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RSS recombination signal sequence 
RT room temperature 
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v/v volume per volume 
WT wildtype 
w/v weight per volume 
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1. Introduction 
 
 
1.1. Immunoglobulin E - IgE 
 
 
1.1.1. Structure of Immunoglobulin E  
 
 
As a result of the seminal studies of Ishizaka, Bennich and Johansson, 
Humphrey and Stanworth, immunoglobulin E was officially implemented in 1968 
at the meeting of the “World Health Organization Immunoglobulin Reference 
Laboratory” (1). Immunoglobulin E has a molecular weight of 190 kD (2). IgE 
shares the same structural domains with the other immunoglobulin isotypes. 
The IgE molecule consists of two identical heavy (H) chains and two identical 
light (L) chains connected by disulfide bounds. The heavy ε-chain contains one 
extra domain compared to other immunoglobulins like IgG (2). Each heavy and 
light chain consists of constant (C) and variable (V) regions. The constant 
regions (Cε1 - Cε4 and CL) are identical in all IgE antibodies whereas the 
variable regions (VH and VL) differ depending on the IgE-producing B cell clone.  
The expression of a unique IgE molecule requires somatic recombination, also 
known as V(D)J recombination (Fig. 1.1). During V(D)J recombination, genes 
encoding the variable region are brought randomly chosen into contiguity from 
dispersed variable (V), diversity (D) and joining (J) elements (3). V, D and J 
segments are found in the VH region whereas the VL region lacks D gene 
segments. Each gene segment contains a recombination signal sequence 
(RSS) which is recognized by recombination-activating gene 1 (RAG1) and 
recombination-activating gene 2 (RAG2). These two enzymes, as a complex, 
cleave the double-stranded DNA between the V, D or J sequence and the 
appropriate RSS, intervening DNA is removed and the V, D or J regions joined. 
During this DNA rearrangement process one of each V, D (when existing) and J 
segments are combined to form a V(D)J exon. The C region lies downstream 
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the V(D)J exon. During RNA splicing the V(D)J exon and the C region exons 
are combined forming mRNA ready to be translated (4).  
 
The Cε3 and Cε4 domain are homologues and share the same quaternary 
structure with the Cγ2 and Cγ3 of the immunoglobulin G concluding that the Cε2 
domains are additional (1).  
 
Furthermore, the immunoglobulin E can be divided into Fab (Fragment, antigen-
binding) and Fc (Fragment, crystalline) fragments (Fig. 1.2). The Fab fragment 
is located at the amino-terminal end of the antibody and is responsible for 
antigen-binding. The Fab fragment is composed of one variable and one 
constant region of each heavy and light chain (2). The Fc fragment is located at 
the carboxy-terminal end. Fc-IgE binds to cell surface receptors like the high-
affinity (FcεRI) and the low-affinity IgE receptor (FcεRII) to initiate its biological 
activity. The Fc fragment is composed of the remaining three constant regions 
of the two heavy chains (2).  
 
 
 
Fig. 1.1. Simplified scheme of V(D)J recombination. During DNA rearrangement one V, one 
D and one J segment are combined. Segments are recombined by RAG1 and RAG2. The C 
region lies downstream the V(D)J exon.  
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ε heavy chain (H) 
light chain (L): λ or κ
  
 
 
Fig. 1.2. Structure of immunoglobulin E. IgE consists of two identical heavy (H) chains and 
two identical light (L) chains. The ε heavy chain is composed of four constant regions (Cε1 - 
Cε4) and one variable region (VH). The light chain is composed of one constant (CL) and one 
variable (VL) region. The immunoglobulin E binds antigen through the amino-terminal end (Fab) 
and can bind on Fc receptors through its carboxy-terminal region (Fc); modified from (1) 
 
 
1.1.2. Physiology of Immunoglobulin E 
 
 
Initially IgE was thought to play a role in pathogen defense only, but due to the 
observation of increasing IgE levels in patients suffering from allergy, it has 
emerged, that IgE plays a crucial role in the development of hypersensitivity 
reactions (1). 
In contrast to other immunoglobulin classes, the concentration of IgE in the 
serum of healthy individuals is very low (30-100 ng/ml compared to 10 mg/ml of 
IgG) (2). In atopic diseases and allergies, the IgE serum concentration can be 
dramatically increased (1, 5). IgE has a half-life of two to three days when free 
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in serum. The half-life of IgE increases up to several weeks when IgE is cell-
bound (2, 6).  
 
Following sensitization to certain antigens under certain conditions, Th2 cells 
are primed and secrete Th2 cytokines including IL-4 and IL-13 (Fig.1.3). These 
cytokines induce a class switch from µ (IgM) to ε (IgE) heavy chain usage and 
subsequent IgE production and secretion by B cells (1).  
Crosslinking of IgE bound to FcεRI on mast cells by allergen leads to mast cell 
activation and to the early-phase of the allergic reaction (EAR). This includes 
mast cell degranulation and subsequent release of histamine and other 
inflammatory mediators (1). Clinically, the EAR manifests as rhinoconjunctivitis, 
urticaria, acute asthma attacks or in the worst case, anaphylaxis (7). Hours after 
the initial allergen encounter the late-phase of allergic reaction (LAR) gradually 
develops. This inflammatory reaction requires the chemokine- and cytokine- 
induced recruitment of leukocytes like Th2 lymphocytes, dendritic cells (DCs), 
and eosinophils to the site of allergen exposure (1). Allergen-specific T cells are 
activated and proliferate in situ. Several lines of evidence show that the LAR is 
strictly dependent on Th2 cells. Th2 cells secrete cytokines like IL-4, IL-5 and 
IL-13 thereby activating effector cells like eosinophils, which can mediate tissue 
damage and mucus production during chronic inflammation (Fig. 1.3).  
In the lung, the LAR includes oedema and erythema of airways, increased 
mucus production, airway obstruction, long-lasting ventilatory insufficiency and 
if untreated, fibrotic lung remodeling (7). The repeated occurrence of LARs 
contributes to chronic allergic symptoms. 
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Fig. 1.3. Effector functions of Th2 cells. Following antigen-specific T cell activation, T cells 
produce IL-4, IL-5 and IL-13 cytokines. IL-4 and IL-13 in turn mediate IgE class switch of B 
cells. IL-13 stimulates epithelial cells / goblet cells leading to mucus production. IL-5 activates 
eosinophils leading to tissue damage. 
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1.2. The high-affinity IgE receptor – FcεRI 
 
 
1.2.1. Expression and structure of the high affinity IgE receptor  
 
 
The high affinity IgE receptor (FcεRI) is expressed in two isoforms. (i) The 
tetrameric (αβγ2) form (Fig. 1.4a) composed of one alpha, one beta and a 
gamma-chain dimer is expressed on mast cells and basophils (8, 9). (ii) In 
humans, the trimeric (αγ2) form (Fig. 1.4b) lacking the beta-chain is expressed 
on Langerhans cells (10, 11), DCs (12, 13), monocytes (14), possibly also 
eosinophils (15) and platelets (16). Noteworthy, mice do not express the trimeric 
form of FcεRI on APCs but express the tetrameric receptor on mast cells and 
basophils.  
 
The FcεRIα-chain is a type I integral membrane protein composed of a C-
terminal transmembrane anchor and one N-terminal extracellular part (17). The 
α-chain is a 50 kDa, highly N-glycosylated subunit: FcεRIα reveals seven N-
glycosylation sites in human (18) and six N-glycosylation sites in mouse (19). 
The extracellular part of the α-chain is composed of two immunoglobulin-like 
domains (D1 and D2) (1) and contains the two IgE binding sites within the D2 
domain. IgE-Fc binds to FcεRIα with a 1:1 stoichiometry and an affinity of Kd < 
10-9-10-10 M (20). 
The β-chain is a 30 kDa subunit of FcεRI with four transmembrane domains. 
The NH2 terminus and COOH terminus are both cytoplasmic. The β-chain 
contains an immunoreceptor tyrosine-based activation motif (ITAM) in the 
cytoplasmic tail near the C terminal end (21). The β-chain amplifies signals 
mediated from the γ-chains (22). The β-chain alone can not account for full 
signaling capacity (23). Furthermore, the β-chain is able to amplify the surface 
expression of FcεRI. This explains the 10-100 fold higher expression of αβγ2 
receptors on mast cells and basophils compared to surface expression of the 
αγ2 receptor (24).  
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The γ-chain is a 10 kDa subunit of the high-affinity IgE receptor. The γ-chains 
form a disulfide-linked homodimer. Each γ-chain consists of a short extracellular 
domain, a transmembrane domain and a cytoplasmic tail. Both γ-chains 
possess an ITAM in its cytoplasmic tail (25). The γ-chain of FcεRI is also a 
subunit from other Fc receptors like FcγRIII (human) and FcγRIIa (mouse) (26). 
Moreover, the γ-chain is required for surface expression of Fc receptors 
including FcεRI (25). 
 
a                b 
            
 
 
 
 
 
 
 
human mouse  human mouse 
mast cells 
basophils  
mast cells 
basophils 
 
Langerhans 
cells 
dendritic cells 
monocytes 
eosinophils 
platelets 
        -  
 
 
Fig. 1.4. Expression and structure of the high-affinity IgE receptor. FcεRI is expressed 
either as tetramer (a) or as trimer (b). The tetrameric form is composed of one alpha, one beta 
and a gamma-chain dimer whereas the trimeric form lacks the beta-chain. The αβγ2 form is 
expressed on mast cells and basophils. The αγ2 form is expressed in humans on Langerhans 
cells, dermal DCs, monocytes, eosinophils, peripheral blood DCs and platelets. The α-chain 
contains the two IgE binding sites within the D2 domain. The β-chain has four transmembrane 
domains and an ITAM in the cytoplasmic tail. The γ-chains form a disulfide-linked (S-S) 
homodimer. Each γ-chain contains an ITAM in its cytoplasmic tail.  
α α β  γ  γ γ  γ 
ITAM ITAM 
D1 
D2   D2 
 
           D1 
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1.2.2. Regulation of FcεRI expression 
 
 
FcεRI cell surface expression is regulated by: (i) the existence of the γ-chain (ii) 
the existence of the β-chain, and (iii) IgE serum concentration and IgE binding 
to the α-chain.  
The existence of the γ-chain is crucial for efficient cell surface transport of 
FcεRI. As we and others showed (Fig. 3.1), transfection of cells with the coding 
sequence for the α-chain only results in cytoplasmic FcεRI+ expression, while 
co-transfection of the coding sequence for the γ-chain is sufficient for efficient 
FcεRI surface expression (27).  
As aforementioned, the β-chain is able to amplify the surface expression of 
FcεRI resulting in 10-100 fold higher expression of αβγ2 receptors on mast cells 
and basophils compared to surface expression of the αγ2 receptors (24). 
In addition, there is a correlation between serum IgE and the density of surface 
expression of FcεRI (28). In healthy subjects, the serum concentration of IgE is 
much lower (about 100 ng/ml) than the concentration of IgG (2). In patients 
suffering from atopic diseases, the IgE serum concentration can dramatically 
increase. Increased serum IgE leads to upregulation of FcεRI surface 
expression by stabilization of FcεRI at the cell surface. Treatment of atopic 
patients with anti-IgE antibodies decreases free serum IgE and subsequent 
surface expression of FcεRI (29). Also, IgE does not influence the mRNA level 
for either α-, β- or γ- chain (30). Thus, the interaction of IgE with FcεRI is a main 
reason of posttranslational upregulation of receptor surface expression (31).  
The effective concentration50 (EC50) for IgE-induced FcεRI upregulation is about 
230 ng/ml (32). The mechanism of IgE-mediated FcεRI upregulation consists of 
three different factors: binding of IgE prevents the loss through receptor 
stabilization at the cell surface, increases the utilization of recycled and export 
of newly synthesized receptors (33).  
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1.2.3. Signaling via FcεRI 
 
 
Following FcεRI aggregation on cell surface cell signaling is initiated (10). 
Aggregation leads to the activation of protein tyrosine kinases (PTKs) of the Src 
family including Lyn and Syk (34). The weakly associated PTK Lyn induces the 
phosphorylation of tyrosine residues within the β-chain ITAM (35). Interacting 
with the phosphorylated β-chain ITAM, additional recruited Lyn promotes the 
phosphorylation of tyrosine residues within the γ-chain ITAMs (22) and form 
binding sites for the PTK Syk. Syk is activated after ITAM binding (36). The PTK 
Syk is phosphorylated by Lyn but can also be autophosphorylated resulting in 
increased activity (37). Downstream events include the phosphorylation of LAT 
(linker for activation of T cells) subsequently essential for further downstream 
events resulting in the release of proinflammatory proteins (38).  
In addition, a second – “complementary” – signaling pathway came up when 
Juan Rivera and his group described a Fyn-kinase dependent pathway (39). 
Within this cascade, Fyn becomes activated after FcεRI aggregation. This leads 
to the phosphorylation of GAB2 (growth-factor receptor-bound protein 2-
associated binding protein 2) and subsequent to the binding of PI3K 
(phosphatidylinositol 3-kinase). Further downstream events result in the release 
of proinflammatory proteins without the requirement of LAT (39).  
The existence of two different expression types of FcεRI raises the question of a 
difference in their signaling capabilities because of the lack of the β-chain within 
the αγ2 complex. Alber et al. showed that cells expressing an αγ2 complex are 
activated normally after FcεRI aggregation and have the ability to activate 
hematopoietic cells (40). The β-chain has the ability to amplify the Fcγ signal 
which leads to an amplified signaling mechanism including Syk activation and 
calcium mobilization (22). Bieber et al. concludes the lack of the β-chain on 
antigen-presenting cells (APCs) to functional differences like the high variability 
in surface expression (41).  
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Fig. 1.5. Simplified scheme of the first events in FcεRI signaling. FcεRI aggregation leads 
to the activation of Lyn and Syk. Lyn induces the phosphorylation of the β-chain ITAM. 
Additional recruited Lyn promotes the phosphorylation of the γ-chain ITAMs and form binding 
sites for Syk which is activated after ITAM binding. Syk is phosphorylated by Lyn but can also 
be autophosphorylated. Downstream events include the phosphorylation of LAT resulting in the 
release of proinflammatory proteins.  
Within the “complementary” signaling pathway Fyn becomes activated after FcεRI aggregation. 
This leads to the phosphorylation of GAB2 and subsequent to the binding of PI3K. Further 
downstream events result in the release of proinflammatory proteins without the requirement of 
LAT.  
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1.2.4. Biological function of FcεRI 
 
 
FcεRI plays a central role in the pathophysiology of type 1 allergic reactions. 
Crosslinking of IgE bound to FcεRI on mast cells by allergen leads to mast cell 
activation and to the EAR which is often followed by a LAR. The characteristic 
chain of events in type 1 immediate allergic reactions includes (i) IgE production 
by B cells in response to allergen exposure, (ii) binding of IgE to Fcε receptors 
on the cell surface of mast cells and basophils, (iii) re-exposure to the same 
antigen which leads to interaction of allergen and FcεRI-bound IgE, and finally 
(iv) crosslinking of Fcε receptors which results in cell activation. Mast cell 
activation is followed by the release of preformed mediators like histamine and 
serotonin as well as the production and secretion of mediators like 
prostaglandins, leukotrienes, cytokines, interleukins and growth factors (7).  
Furthermore, recent studies indicated an antigen-independent function of FcεRI. 
Asai et al. showed that IgE alone can partially activate FcεRI and enhance the 
survival of mast cells (42). Consequently, FcεRI bound monomeric IgE can 
increase allergic reactions not only by regulation of FcεRI expression, but also 
by regulation of mast cell homeostasis.  
FcεRI on antigen-presenting cells enhances T cell activation. DCs can take up 
IgE-bound antigens, process them and present allergen-derived peptides. 
Maurer et al. showed that DCs from allergic patients more efficiently present 
allergen-derived peptide to T cells in the presence of allergen-specific IgE (43).  
Furthermore, human epidermal Langerhans cells express FcεRI (11, 12). 
Jürgens et al. showed that crosslinking of FcεRI on Langerhans cells derived 
from patients with atopic dermatitis but not from healthy individuals results in 
calcium mobilization (44). In addition, upregulation of protein tyrosine kinases 
and subsequent activation of phospholipase C-γ1 (PLCγ1), essential for calcium 
mobilization, was detected only in Langerhans cells from atopic patients and not 
from healthy individuals (45). Moreover, crosslinking of FcεRI expressed on 
Langerhans cells of atopic patients leads to NF-κB activation which in turn 
results in the synthesis and secretion of proinflammatory cytokines like TNFα 
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and MCP-1 (46). To conclude, FcεRI expressed on antigen-presenting cells 
influences inflammatory and allergic reactions.  
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1.3. Dendritic cells and antigen-presentation 
 
 
Skin cells with a “dendritic” nerve cell-like morphology were first described by 
Paul Langerhans in 1868. Today we know that Langerhans cells belong to the 
family of dendritic APCs. The term “dendritic cell” was coined in 1973 by Ralph 
M. Steinman and Zanvil A. Cohn to describe a previously unrecognized bone-
marrow-derived cell species in peripheral lymphoid organs that has the unique 
ability to MHC-dependently activate resting T cells (47).  
 
 
1.3.1. DC maturation and Th differentiation in response to DC stimuli 
 
 
DCs have the ability to regulate immune responses: immunity against tolerance 
and Th1 against Th2. This ability is dependent on their state of maturation and 
the quality of the signals which they receive from the environment. Immature 
DCs are located in the peripheral tissues and are recruited into sites of 
inflammation where they have the ability to take up and process antigen. 
Following the receipt of certain signals (e.g. bacteria, viral products, 
inflammatory cytokines), DCs mature and migrate to lymphoid organs where 
they present allergen-derived peptides in the context of MHC molecules to T 
cells (48; Fig. 1.6). During DC maturation biologically important alterations 
occur: (i) upregulation and clustering of MHC (MHC-peptide complexes), B7 
(CD80 and CD86) and CD40 molecules (49), (ii) synthesis of cytokines and 
chemokines (50) and (iii) switch in surface expression of chemokine receptors 
to control DC movement to lymphoid organs, e.g. upregulation of CCR7 to 
ensure DC homing to secondary lymphoid tissues (51).  
The upregulation of MHC-peptide complexes determines the specificity of T cell 
response (signal 1) whereas the expression of B7 molecules allows expansion 
of T cells (signal 2). Furthermore DCs secrete cytokines (signal 3) in part in a 
polarized fashion towards the activated T cell which differ dependent on the 
nature of stimulus, stage of DC maturation and the already existing 
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environmental cytokines, determining the differentiation of naïve Th cells (ThN) 
towards Th1, Th2, Th17 and regulatory T cells (52, 53, Fig 1.7).  
 
Key cytokines secreted by DCs include e.g. IL-2, IL-6, IL-10, IL-12, IL-18, IFN-α, 
IFN-ß, IFN-γ, TNF-α. Receiving lipopolysaccharide (LPS), poly(I:C), bacterial or 
viral signals, DCs secrete IL-12, the main Th1 polarizing cytokine, stimulating 
IFN-γ production in naïve T cells and promoting Th1 polarization. Engagement 
of CD40 on DCs with CD40 ligand (CD40L) primes mature DCs for maximal 
expression of IL-12. Binding of IL-12 to its appropriate receptor on antigen-
stimulated CD4+ T cells activates the transcription factors STAT1 and 4 (54). 
STAT1 stimulates the expression of T-bet which promotes IFN-γ production. 
STAT4 enhances IFN-γ production and seems to be an important factor in Th1 
polarization since STAT4-/- mice show decreased secretion of IFN-γ and are 
defective in Th1 cell development (55). Moreover, IFN-γ augments its own 
expression by a STAT1-dependent positive feedback loop. Another Th1 
polarizing cytokine secreted by DCs is IL-18. IL-18, unlike IL-12, only induces 
low levels of IFN-γ but in presence of IL-12 acts as a strong agonist (53). Type 1 
interferons (IFN-α, β and ω) secreted by DCs also promote Th1 differentiation 
by activation of STAT4 in human but not murine T cells (56).  
Receiving microbial or allergenic signals that cause repeated CD4+ T cell 
stimulation, DCs stimulate the differentiation of naïve Th cells towards Th2 cells. 
One important event in Th2 differentiation can be the downregulation of IL-12 
secretion. Furthermore, differentiation of T cells into Th2 cells depends on IL-4. 
Mainly, the Th cell itself produces IL-4, which is dependent on the activation of 
STAT6. The transcription factor STAT6 induces the expression of GATA3, the 
main transcription factor in Th2 differentiation by enhancing the expression of 
IL-4, IL-5 and IL-13 (57). Expressed GATA3 augments its own expression by a 
positive feedback loop (58) and inhibits IL-12 signaling by downregulation of IL-
12 receptor β2-chain (IL-12Rβ2) expression (59).  
The fact that differentiated CD4+ Th2 cells are the main producers of IL-4 raises 
the question where does IL-4 originate before Th2 cell differentiation. ThN cells 
are capable of low-level secretion of IL-4, which will gradually enhance during 
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persistent low level antigen stimulation. Furthermore, other cells may be the 
source of IL-4 as Kelleher et al. showed the ability of Rauscher leukemia virus 
(RLV)-treated DCs to produce IL-4 (60). Crosslinking of FcεRI on mast cells and 
basophils is an essential event in the induction of allergic inflammation. Thus, 
these effector cells may be a source of IL-4. Plaut et al. demonstrated the 
capability of murine mast cells to secrete IL-4 and IL-5 upon FcεRI crosslinking 
(61) and Bradding et al. showed also human mast cells produce IL-4 (62). 
Basophils may be an additional source of the Th2-cytokine IL-4. Brunner et al. 
showed that basophils produce IL-4 after FcεRI stimulation (63), whereas 
studies by MacGlashan et al. indicate that basophils express IL-4 message 
even constitutively and upregulate IL-4 secretion after stimulation (64).  
ThN cells can also differentiate into Th17 cells characterized by the secretion of 
IL-17. Th17 cells are pro-inflammatory (65) and play an essential role in 
defense against various bacteria and fungi. Th17 cells do not secrete IL-4 or 
IFN-γ and their differentiation is even antagonized by IL-4 and IFN-γ (66). The 
cytokines IL-6 and TGF-β are essential for the generation of Th17 cells (67) 
whereas IL-21 amplifies Th17 differentiation and IL-23 promotes the 
maintenance of Th17 cells (68).  
DCs have also the capability of regulatory T cell induction. Regulatory T (Treg) 
cells can be distinguished between naturally occurring (nTreg) and induced 
regulatory T (iTreg) cells. nTreg cells are thymic derived CD4+CD25+Foxp3+ 
Treg cells. iTreg cells are generated from peripheral ThN cells after activation 
by antigen-presenting DCs (53). Jonuleit et al. showed that immature DCs 
induce iTreg differentiation after repetitive stimulation (69) and McGuirk et al. 
demonstrated that pathogen-activated (e.g. Bordetella pertussis-treated) DCs 
can also induce iTreg development (70). In all studies, IL-10 plays an essential 
role in iTreg differentiation. Culture of human ThN cells with IL-10 results in the 
development of iTreg cells suppressing other Th cell proliferative responses 
(71). IL-10 indirectly influences tolerance since IL-10 inhibits full DC maturation, 
upregulation of costimulatory molecules and DC-dependent IL-12 secretion 
(72).  
 
Mitterhumer Eva            Introduction 
 
 30 
 inflammatory cytokines 
  TNF-α 
     IL-1 
       or bacterial stimuli 
         or viral products 
 
a                            b 
 
        upregulation of 
      MHC I 
      MHC II 
      CD40 
 
      CD80 
      CD86 
      CCR7  
 
  antigen-uptake     T-cell priming  
 
 
Fig. 1.6. DC-maturation. There are two states of DCs. (a) Immature DCs and (b) mature DCs. 
Stimuli like inflammatory cytokines or bacterial stimuli induce DC maturation thus including a 
phenotypic and functional alteration. Surface expression of MHC molecules, chemokine 
receptors and secretion of chemokines are upregulated. 
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Fig. 1.7. Simplified scheme of Th subset development. Naïve T cells can differentiate into 
Th1, Th2, Th17 and regulatory T cells, depending on the signal they receive. IL-12 induces the 
differentiation towards Th1 and IL-4 towards Th2. IL-6 and TGF-β are essential for Th17 
differentiation, whereas IL-10 acts in the development of regulatory T cells.  
 
 
1.3.2. Antigen-uptake and presentation 
 
 
To induce a T cell response, DCs have to present peptide in the context of MHC 
class I or II molecules expressed on their cell surface.  
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1.3.2.1.  MHC class I presentation 
 
 
Intracellular antigens like intracellular bacteria or viruses are presented by MHC 
class I molecules to CD8+ T cells (Fig. 1.8). The endogenous antigen is 
processed by the proteasome into small peptides. These peptides are 
transported via TAP (transporter associated with antigen presentation) into the 
endoplasmic reticulum (ER). In the ER, peptides are loaded onto newly 
synthesized MHC class I molecules. Peptide-loaded MHC molecules are 
transported through the Golgi apparatus to the cell surface (73).  
 
 
Fig. 1.8. MHC class I presentation. Endogenous antigen is degraded in the proteasome and 
transported via TAP into the ER. Peptides are loaded onto newly synthesized MHC class I 
molecules. Loaded MHC class I molecules are transported via the Golgi to the cell surface, 
where the peptide is presented to CD8+ T cells. TAP transporter associated with antigen 
presentation; ER endoplasmic reticulum; APC antigen presenting cell; modified from (50). 
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1.3.2.2. MHC class II presentation 
 
 
Exogenous protein-derived peptides are presented in the context of MHC class 
II molecules to CD4+ T helper cells (Fig. 1.9). DCs use phagocytosis or 
receptor-mediated antigen-uptake to internalize antigen and form the 
phagosome, which contains the sampled antigen (74). The phagosome fuses 
with the lysosome where the internalized antigen is processed. MHC class II 
molecules are synthesized into the endoplasmic reticulum (ER). To prevent 
MHC class II molecules of unintentional binding, the binding groove of the MHC 
class II molecule is occupied by the invariant chain Ii. Ii has further the function 
to determine the transport route of MHC class II molecules through the Golgi in 
the endosomal pathway (75). Vesicles containing the MHC class II molecule are 
delivered from the Golgi complex and associate with the phagosome / lysosome 
containing the degraded antigen. Ii is degraded leaving a short peptide – CLIP – 
in the binding groove (76). Activation of HLA-DM (in mouse H-2M) leads to the 
removal of CLIP and mediates the formation of a stable peptide-MHC class II 
complex ready for cell surface expression (77).  
 
 
1.3.2.3.  Cross-presentation 
 
 
DCs, in contrast to most other APCs, have the capacity to cross-present 
peptides (Fig. 1.10). Usually, the MHC class I pathway is restricted to the 
presentation of peptides derived from endogenous antigens. In DCs, the 
discrimination between MHC class I presentation of endogenous proteins and 
MHC class II presentation of exogenous antigens is not strict. DCs may also 
present exogenous antigens via the MHC class I pathway, referred as “cross-
presentation” (73). The mechanism of cross-presentation is not fully 
understood. Recent studies showed that the phagosome containing exogenous 
antigens fuses with the ER that in turn contains newly synthesized MHC class I 
molecules and the TAP protein. Alternatively, exogenous antigens can be 
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transported into the DC cytosol and undergo conventional proteasomal 
degradation. Resulting peptides are transported via TAP into the ER entering 
the classical MHC class I pathway (78).  
 
 
 
 
 
 
Fig. 1.9. MHC class II presentation. Extracellular antigens are phagocytized and processed in 
the phagolysosome. MHC class II molecules are synthesized into the ER and the peptide 
binding site is occupied by Ii. MHC class II molecules are transported through the Golgi to the 
lysosome. Ii is degraded leaving CLIP in the binding groove. Through activation of HLA-DM / 
H2-M CLIP is removed followed by the formation of a stable MHC class II-peptide complex 
which is transported to the cell surface to present peptides to CD4+ T cells. ER endoplasmic 
reticulum; APC antigen presenting cell; modified from (50). 
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Fig. 1.10. Cross-presentation. Exogenous antigens are presented on MHC class I molecules 
to CD8+ T cells. The phagosome containing the antigen fuses with the ER. The antigen is 
transported into the cytosol where it is degraded by the proteasome. Peptides are transported 
via TAP into the ER. Peptides are loaded onto newly synthesized MHC class I molecules. 
Loaded MHC class I molecules are transported via the Golgi to the cell surface, where the 
peptide is presented to CD8+ T cells. TAP transporter associated with antigen presentation; ER 
endoplasmic reticulum; APC antigen presenting cell; modified from (73). 
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1.3.3. Murine dendritic cell subtypes 
 
 
DCs can be divided in subtypes differing in function and expression of surface 
markers (Tab. 1.1). Basically, DCs can be divided into plasmacytoid and 
conventional DCs. Plasmacytoid DCs (pDCs) express the surface markers 
CD11clow and B220. After viral stimulation via endosomal pDC-expressed TLR7 
(recognizes ssRNA) and TLR9 (recognizes unmethylated CpG DNA) (75), 
interferon regulatory factor 7 (IRF7) is activated (80) and type I IFNs (IFN-α/β), 
mainly IFN-α are transcribed and secreted by pDCs (81, Fig. 1.11). Contrary to 
other cell types, pDCs are not reliant on IRF3 in the activation of IFN genes 
since pDCs from IRF3-/- mice produce the same amounts of IFN as pDCs from 
WT mice. (82). Type I IFNs bind to the IFN-α receptor (IFNAR) composed of 
two subunits, IFNAR1 and IFNAR2. IFNAR1 and IFNAR2 are associated with 
the Janus family tyrosine kinases Tyk2 and Jak1, respectively. Upon IFN 
binding Tyk2 and Jak1 become activated leading to phosphorylation of STAT1 
and STAT2 (83), formation of STAT1/STAT2 dimers and recruitment of IRF9. 
STAT1/STAT2 dimers and IRF9 proteins form trimeric complexes which 
translocate into the nucleus and induce the activation of gene transcription as a 
result of trimer binding to IFN-stimulated response elements (ISREs) (84, Fig. 
1.12). Type I IFN induced gene transcription includes e.g. the synthesis of 
enzymes like serine/threonine protein kinase (PKR16) and RNase L18 resulting 
in viral transcription/translation blocking and viral RNA degradation, 
respectively. pDCs appear not play a crucial role in antigen-presentation, but 
their secretion of large amounts of IFN-α is essential for blocking viral 
replication and may contribute to prime other DC subtypes (73). Conventional 
DCs can be further divided into five subtypes. Due to the expression of CD4 
and CD8, three subtypes can be distinguished. There are CD11c+CD8+CD4- 
lymphoid DCs, CD11c+CD8-CD4+ myeloid DCs and CD11c+CD8-CD4- DCs 
(85). Conventional DCs have the ability to present protein-derived peptides in 
the context of MHC molecules to T cells and induce the immune response. 
Furthermore CD8+ DCs have also the ability of cross-presentation and cross-
priming (73). The remaining two DC subtypes are Langerhans cells and 
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interstitial dermal DCs (DDC). They are characterized by their expression of 
DEC-205 (86). Langerhans cells and DDCs can further be distinguished by the 
different level expression of DEC-205 (high on Langerhans cells and 
intermediate on dermal DCs). Langerin was thought to distinguish between 
Langerhans cells and DDC (87) but recent studies showed a population of 
Langerin+ DDCs. Bursch et al. demonstrated that the expression of the cell 
adhesion molecule EpCAM allows distinguishing Langerhans cells from 
EpCAM- DDCs (88, 89). Langerhans cells and DDCs have the capacity of self-
renewal under stady-state conditions within the skin (90). Only after skin injury 
caused by e.g. UV irradiation, depleted DCs are replaced by circulating 
precursors (91). Langerhans cells capture antigen in the skin and carry them to 
the draining lymph nodes where they prime T cells and induce immune 
responses (92). DDCs have been described to mainly induce CD4+ T cell 
responses (93, 94).  
 
 
   surface marker 
DC subtype CD11c CD4 CD8 B220 DEC-205 
CD4+ DC + + - - - 
CD8+ DC + - + - + 
CD4- CD8- DC + - - - - 
Langerhans cells + - - - high 
dermal DCs + - - - + 
plasmacytoid DC + +/- +/- + - 
 
 
Table 1.1. Surface expression markers of DC subtypes. DCs can be divided into six 
subtypes. The main discrimination is made between plasmacytoid DCs (pDCs) and 
conventional DCs. Conventional DCs can further be divided through the surface expression of 
CD4 and CD8. Additional, there are Langerhans cells and dermal DCs; modified from (73) 
 
Mitterhumer Eva            Introduction 
 
 38 
 
 
Fig. 1.11. Production of IFN-α/β. After viral stimulation via endosomal pDCs-expressed TLR7 
and TLR9, IRF7 is activated and type IFNs are transcribed; modified from (4) 
 
 
 
Fig. 1.12. Response to type I IFNs. Type I IFNs bind to IFNAR. The two subunits, IFNAR1 
and IFNAR2, are associated with Tyk2 and Jak1, respectively. Upon IFN binding Tyk2 and Jak1 
become activated leading to phosphorylation of STAT1 and STAT2, formation of STAT1/STAT2 
dimers and recruitment of IRF9. STAT1/STAT2 dimers and IRF9 proteins form trimeric 
complexes which translocate into the nucleus and induce the activation of gene transcription as 
a result of trimer binding to ISREs; modified from (4). 
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1.3.4. Dendritic cells in the lung 
 
 
DCs are found in all lymphoid organs (47), in the blood (95), in the bone marrow 
(96) as well as in other organs like the lung (97). Within the lung, DCs are 
localized in the airway epithelium, lung parenchyma and pleura (97). DCs and 
macrophages, both are APCs expressing CD11c on their cell surface. DCs are 
more potent stimulators of immune responses than macrophages. Thus, 
discrimination of these two populations is indeed important. CD11b can not be 
used as marker for discrimination between pulmonary macrophages and DCs. 
Pulmonary macrophages in general and various DCs, depending on their 
anatomical location, express CD11b. Vermaelen et al. studied the accurate 
discrimination of lung DCs and macrophages by their expression of CD11c and 
their level of autofluorescence (98) and showed a clear discrimination of two 
populations among CD11c-bright lung cells. Characteristics of autofluorescence 
allow discrimination between CD11c+ lung DCs and CD11c+ macrophages: low 
autofluorescent DCs can easily be distinguished from high autofluorescent 
macrophages (99).  
DCs are present both in normal and in inflamed lung tissue. However, 
inflammatory stimuli increase the number of DCs in the lung (100).  
Due to the location of DCs within the lung and their capacity of efficient antigen-
presentation, DCs seem to be important also in allergic lung inflammation. 
Lambrecht et al. showed that depletion of DCs during the induction of airway 
inflammation results in an almost totally suppressed eosinophil-dependent 
inflammation (101).  
In addition, pulmonary DCs in humans express FcεRI. Comparing the number 
of FcεRI+ DCs in normal and asthmatic airways, Tunon-De-Lara and colleagues 
demonstrated an increase of FcεRIα-expressing DCs in asthma. Thus, FcεRI 
expression on DCs may contribute to the occurrence and the regulation of 
magnitude of allergic lung inflammation (102). 
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1.4. Allergy and atopic diseases 
 
 
“The conception that antibodies, which should protect against disease, are also 
responsible for disease, sounds at first absurd. “ (Clemens von Pirquet, 1906) 
 
Clemens von Pirquet first introduced the term “allergy” in 1906 to describe a 
disease complex that is mediated by altered reactivity of the immune system 
(103). In 1963, Gell and Coomb classified hypersensitivity reactions into four 
groups whereas IgE-mediated allergy was referred as type 1 (immediate) 
hypersensitivity reaction (104). Allergic diseases include rhinoconjunctivitis, 
allergic asthma, atopic dermatitis and food anaphylaxis. Pathophysiologically, 
type 1 hypersensitivity reactions can be divided into two phases: (i) the EAR 
occurs within minutes after allergen exposure and (ii) the LAR, which persists 
for hours to days.  
 
 
1.4.1. Causes of allergy 
 
 
1.4.1.1. Allergens 
 
 
“What makes an allergen to allergen?” (Kjell Aas, 1978). Molecular investigation 
showed some common characteristics of allergens: Allergens are soluble and 
stable proteins, many of them having enzymatic function. Furthermore, the 
allergenic property of an antigen depends on the particle size (105), normally 
ranging from 5 to 80 kDa. Allergens are classified according to their origin (e.g. 
food allergens, allergens of animal hair, pollen allergens) and to their mode of 
entry (e.g. inhalation, food).  
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1.4.1.2. Genetic predisposition 
 
 
Family and twin studies allow an investigation in the predisposition for allergies. 
Family studies showed that children from healthy individuals have a relative risk 
ranging from 9 to 18% to develop allergies. The risk to develop an allergic 
disease for children with one parent being atopic is about 50% and with both 
parents being atopic even 70% (106). Comparing monozygotic and dizygotic 
twins, Hopp et al. showed a heritability of total serum IgE, methacholine 
sensitivity and total skin test scores (107). Studies on chromosomal regions 
relevant for the development of allergies identified e.g. chromosome 11q13 
encoding the β-chain of FcεRI (108, 109) and 5q31-33 encoding for Th2 
cytokines like IL-4 and IL-5 (110). Holt et al. showed an association of allergy 
with delayed postnatal maturation of T-cell competence: the capacity of T cells 
from children with family risk for atopy to produce IFN-γ is significantly 
decreased (111). 
 
 
1.4.1.3. Hygiene hypothesis 
 
 
In 1989, David P. Strachan first hypothesized an inverse relation between 
allergic disease and household size due to transmission of more bacterial and 
viral infections in these families (112). This hypothesis is used to link the 
increased prevalence of allergic disease in developed countries with reduced 
exposure to bacteria, viruses and microbes in modern civilizations. The possible 
mechanism behind is a suppression of Th2-mediated allergic responses 
through bacterial or virus-elicited Th1 immune response during early life. 
Supporting the hygiene hypothesis, Matricardi et al. demonstrated that 
exposure to foodborne and orofecal microbes results in less frequent 
occurrence of respiratory allergy (113). Conversely, contradicting the hygiene 
hypothesis, Benn et al. showed that early infections do not protect from allergic 
disease (114). Recent studies favored a different model: regulatory T cells 
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balance Th1 and Th2 responses by secretion of regulatory cytokines (IL-10 and 
TGF-β) (115) and are decisive in the development of allergic disease. How their 
generation and function are linked to the theorem of the hygiene theory remains 
to be elucidated.  
 
 
1.4.2. Reactions of type 1 allergic hypersensitivity 
 
 
Type 1 allergic hypersensitivity consists of an early (EAR) and a late-phase 
allergic reaction (LAR). The EAR occurs within seconds to minutes after re-
exposure to an antigen whereas the LAR develops 2 – 24 h later. 
 
 
1.4.2.1. The early-phase allergic reaction 
 
 
Upon first exposure to antigen, APCs take up antigen, migrate to lymph nodes, 
process the antigen and present antigen-derived peptides to naïve CD4+ T 
cells. T cells differentiate into Th2 cells secreting IL-4 and IL-13 and thus 
promote heavy chain isotype switching in allergen-specific B cells and IgE 
secretion. Circulating allergen-specific IgE binds to FcεRI receptors on the cell 
surface of mast cells and basophils. Re-exposure to the same antigen leads to 
interaction of allergen and FcεRI-bound IgE and thus crosslinking of FcεRI-
bound IgE resulting in mast cell/basophil activation. This cell activation includes 
(i) release of preformed mediators (e.g. histamine), (ii) new synthesis and 
secretion of lipid mediators (e.g. leukotrienes) and (iii) new synthesis and 
secretion of cytokines (e.g. TNF) (116). Mast cells are the most crucial cell type 
in the EAR. The necessity of FcεRI expressed on mast cells was demonstrated 
in a study by Dombrowicz et al. using FcεRIα-/- mice. After intravenous IgE-
injection, FcεRIα-/- mice, in contrast to WT mice, fail to develop cutaneous and 
systemic anaphylaxis (117). 
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1.4.2.2. The late-phase allergic reaction  
 
 
The LAR developing hours after allergen re-exposure may follow the EAR. 
Cytokines and chemokines secreted during the EAR initiate the LAR. The LAR 
is characterized by recruitment and activation of leukocytes like DCs, T 
lymphocytes and eosinophils to sites of allergen exposure (1). Th2 cells do not 
only play an essential role in the induction of EARs, LARs are strictly Th2 cell-
dependent allergic responses. Th2 cells secrete cytokines like IL-4, IL-5 and IL-
13 (118). IL-4 promotes the production of IgE by B cells (1), IL-13 stimulates 
epithelial cells leading to increased mucus production (119) and IL-5 activates 
eosinophils (120). Eosinophils are normally not present in peripheral tissue. 
After IL-5 dependent activation and chemokine (e.g. eotaxin, RANTES) 
attraction eosinophils are recruited to sites of inflammation. Robinson et al. 
showed in a study examining patients with atopic asthma an increase of Th2 
cell activation, Th2 cytokine mRNA expression and eosinophils recruitment after 
allergen challenge concluding that Th2 produced cytokines directly contribute to 
the magnitude of LARs (121). Furthermore, studies using IL-4 neutralization or 
IL-4-/- mice demonstrate that Th2 cytokines are required for the development of 
LARs since the lack of IL-4 reduces eosinophilic inflammation of the lung (122). 
The LAR differs from classical delayed-type hypersensitivity reactions (DTH) in 
which Th1 but not Th2 cells are most important. Constant and repeated allergen 
exposure results in chronic allergic inflammation and irreversible tissue 
damage.  
LARs may occur independently of EARs. This was shown in studies using mast 
cell-deficient mice (123). Moreover, in IgE-deficient mice, eosinophilic bronchial 
inflammation develops normally (124). Thus, these studies demonstrate that 
IgE, mast cells and FcεRI-expressed on mast cells are not important for the 
development of LARs.  
In contrast to mice, human LARs are IgE-dependent. Anti-IgE treatment studies 
in human asthmatic revealed that application of a humanized murine 
monoclonal antibody directed to the FcεRI-binding domain of IgE decreases 
serum IgE and drastically reduces the LAR (125). 
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Fig. 1.13. Type 1 allergic hypersensitivity. Type 1 hypersensitivity consists of the EAR and 
the LAR. They are initiated by exposure to an antigen, followed by differentiation of ThN cells 
into Th2 cells and production of antigen-specific IgE by B cells. IgE binds to FcεRI on mast 
cells. Crosslinking of FcεRI by allergen leads to mast cell activation and the release of 
preformed mediators and the synthesis of cytokines; modified from (4). 
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1.5. α-DC transgenic mice: the tool of my study 
 
 
FcεRI is expressed in two isoforms: (i) the tetrameric form composed of one 
alpha, one beta and two gamma-chains is expressed in humans and mice on 
mast cells and basophils; (ii) the trimeric form lacking the beta-chain is only 
expressed in humans and not in mice.  
 
To study the in vivo role of FcεRI on DCs, our laboratory has generated α-DC 
TG mice. These mice display an overall “human-like” FcεRI expression pattern 
which allowed us to study this receptor’s contribution to immunity and allergic 
reactions in a fashion reflecting the human situation. 
The transgenic construct generated is driven by a CD11c promoter that induces 
transcription of the human FcεRIα-chain and the fluorescent dye eGFP in a 
simultaneous fashion selectively on DCs (Fig. 1.9).  
 
 
 
 
 
 
Fig. 1.14. Construct for constitutive DC-targeted expression of FcεRI. CD11c promoter 
(pCD11c)-driven bicistronic construct for DC-targeted expression of huFcεRIα and eGFP; IRES, 
internal ribosome entry site. 
 
pCD11c huFcεRIα IRES eGFP 
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1.6. Overall aim and concept of this study 
 
 
Allergic inflammation is a severe disease whose incidence has increased over 
the last few decades. Allergic asthma is characterized by chronic inflammation 
of the lung and mucus overproduction. Type 1 allergic reactions consist of an 
early (EAR) and a late-phase allergic reaction (LAR). During the EAR, 
crosslinking of IgE/allergen complexes bound to FcεRI on mast cells leads to 
mast cell activation. This includes the release of preformed, pharmacologically 
active mediators like histamine and serotonin as well as the production and 
secretion of mediators like prostaglandins, leukotrienes, cytokines, interleukins 
and growth factors (7). EARs occur within minutes after allergen exposure but, 
by definition, are short-lived. In many instances the EAR is followed by a 
delayed-type inflammatory response, the LAR. Unlike EARs, LARs are 
characterized by chemokine and cytokine-induced recruitment of leukocytes like 
DCs, T lymphocytes and eosinophils to sites of allergen exposure (1) resulting 
in tissue inflammation, mucus production and allergic asthma. Frequent 
occurrence of severe LARs can cause irreversible fibrotic lung pathology. As a 
consequence, LARs, even more the EARs, are the main reason of morbidity 
and mortality in human type 1 allergy (126).  
 
Mechanistically, the EAR and the LAR in humans are clearly independent as 
e.g. shown by the inability to prevent LAR-associated lung inflammation using 
drugs that inhibit mast cell secretion or the subsequent effects of their 
mediators. Despite evident mechanistic dissociation of the mast cell-mediated 
EAR and the LAR, they both are driven by IgE in humans. This was clearly 
shown in IgE neutralization studies in asthmatic patients. Thus, cells other than 
mast cells respond to IgE and are pathophysiologically relevant for the 
elicitation of human LARs. 
 
Besides its presence on mast cells, FcεRI is also expressed on human antigen-
presenting cells such as DCs in various tissues like the lung. FcεRI expressed 
by DCs amplifies allergen-specific T cell responses in atopy (12). However, the 
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in vivo relevance of FcεRI on DCs in the induction of allergic inflammation in 
peripheral tissues like the lung remains unknown. This is probably due to the 
lack of a suitable mouse model to study the role of FcεRI in allergic reactions. 
Noteworthy, mice express FcεRI on mast cells and basophils but lack the 
expression on APCs and are thus no suitable animal model to investigate in the 
in vivo role of FcεRI on APCs. In order to obtain a powerful mouse model to 
study allergic reactions in the respiratory tract in a fashion relevant for human 
allergic inflammation, our laboratory has generated transgenic mice that display 
a “humanized” cellular FcεRI expression pattern. In this α-DC TG mouse line 
expression of the human FcεRIα is driven by the DC-specific CD11c promoter. 
This transgenic mouse model is the tool of my study to define the importance of 
FcεRI for DC function, T cell activation and, subsequently, its contribution to 
atopic inflammation in the respiratory tract. 
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2. Materials and Methods 
 
 
2.1. Culture media 
 
2.1.1. Culture medium for CHO transfectants 
 
10 %    FCS 
2 mM    L-glutamine 
100 U/ml   penicillin 
100 µg/ml   streptomycin 
add IMDM ad 500 ml 
filter sterile (0.22 µm) 
 
 
2.1.2. Culture medium for JW8/5/13 cells 
 
2 mM    L-glutamine 
add CD Hybridoma Medium ad 1000 ml 
 
 
2.1.3. Culture medium for proliferation assays 
 
10 %    FCS 
2 mM    L-glutamine 
100 U/ml   penicillin 
100 µg/ml   streptomycin 
10 mM   HEPES 
1 mM    sodium pyruvate 
0.5 mM   β-mercaptoethanol 
1 x    non-essential amino acids 
add RPMI 1640 ad 500 ml 
filter sterile (0.22 µm) 
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2.1.4. Washing medium 
 
10 %    FCS 
2 mM    L-glutamine 
100 U/ml   penicillin 
100 µg/ml   streptomycin 
add RPMI 1640 ad 500 ml 
filter sterile (0.22 µm) 
 
 
2.2. Buffers 
 
 
2.2.1. Erythrocyte lysis buffer 
 
0.15 M  NH4Cl   8.29 g 
1 mM    KHCO3  1 g 
0.1 mM  EDTA   37.2 mg 
add ddH2O ad 800 ml 
adjust pH to 7.2 – 7.4 with HCl 
add ddH2O ad 1000 ml  
filter, store at RT 
 
 
2.2.2. MACS buffer 
 
0.5 %   BSA 
2 mM    EDTA 
add 1x PBS ad 400 ml 
adjust pH to 7.2 
add 1x PBS ad 500 ml 
filter and store at 4°C  
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2.2.3. Biotinylation buffer 
 
0.1 M   NaHCO3  8.4 g 
  1 M    NaCl   58.4 g 
add ddH2O ad 1000 ml  
 
 
2.3. Cell lines 
 
 
Chinese hamster Ovary (CHO) transfectants, coexpressing the human FcεRIα- 
and FcεRIγ-chain (CHOαγ) have been previously described (11). CHOαγ were 
used to test IgE binding.  
JW8/5/13 cells were purchased from ECACC. The hybridoma cell line JW8/5/13 
(transfected DNA: mouse VH gene + human C (epsilon) gene) secretes 
chimeric IgE anti-NP.  
 
 
2.4. Propagation of adherent cells 
 
 
- remove medium 
- flush 75 cm2 culture flask with 10 ml PBS 
- add 5 ml of Trypsin/EDTA solution 
- incubate at RT until the cells disassociate from the culture flask (careful 
knocking) 
- take 500 µl of Trypsin/EDTA- cell suspension 
- wash the cells with washing medium 
- resuspend cell pellet in 5 ml culture medium  
- add 15 ml of culture medium into a new 75 cm2 culture flask  
- add 5 ml of cell suspension 
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- add 1.28 mg of Geneticin (microbiological potency of 516 µg/ml) /ml 
medium (selection on stable αγ-transfectants) 
- incubate for 3 – 4 days at 37 °C, 5 % CO 2 and 95 % relative humidity 
 
 
2.5. Cultivation of JW8/5/13 cells 
 
 
We used the hybridoma cell line JW8/5/13, to produce chimeric IgEαNP. Cell 
culture supernatant or purified IgEαNP was used for experimentation.  
 
- culture cells in CD Hybridoma medium supplemented with 2 mM L-
glutamine 
- change medium every 3 – 4 days  
- incubate cells at 37 °C, 5 % CO 2 and 95 % relative humidity 
 
 
2.6. Biotinylation of proteins 
 
 
- adjust protein to a concentration of 1 mg/ml 
- dialyze against biotinylation buffer ON at 4 °C  
- solve biotin-X-NHS in DMF (10 mg/ml) 
- add 10 µl of biotin-X-NHS in DMF to 1 ml antibody drop by drop 
- rotate 3 h at RT 
- dialyze against PBS ON at 4 °C  
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 tg PCR +   - 
2.7.  Mice  
 
 
Male and female C57BL/6, BALB/c, OT-II and DO11.10 mice were obtained 
from the Jackson Laboratory. IgE-/- mice were a gift from H.C. Oettgen. 
Generation of the α-DC TG mice was created in our laboratory. Under the 
control of the constitutively active CD11c promoter, mice express the IgE 
binding human FcεRIα-chain and eGFP (Fig. 1.14). Southern Blot analysis of 
DNA isolated from mouse tails shows presence of huFcεRIα-DNA sequence in 
α-DC TG mice but not in wildtype (WT) littermate controls (Fig 2.1). The 
transgenic strain was bred on both BALB/c and C57BL/6 backgrounds. α-DC 
TG mice were crossed into the IgE-/- BALB/c background. Mice were genotyped 
by PCR amplification of mouse tail DNA. All mice were housed under specific 
pathogen-free conditions. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. Southern blot analysis of DNA extracted from α-DC TG (left lane) and WT mice 
(right lane). Existence of transgenic DNA was verified using α32P dATP-labelled hybridization 
probe.  
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2.8.  Immunization and lung challenge  
 
 
Mice were immunized with 100 µg Ovalbumin (Ova) dissolved in PBS 
intraperitoneally four times in one week intervals. Control mice were injected 
with PBS alone.  
Allergic asthma was induced after immunization by aerosol challenge with 4 % 
(w/v) Ova one week after the last i.p. immunization on two successive days. 
Three days later, mice were sacrificed.  
 
 
            aerosol  
challenge 
 
 
                 i.p. 
 
     0              7           14         21  28   29         32 
 
 
 
  
              i.p. 100 µg Ova              aerosol      sacrifice 
                 challenge 
 
Fig. 2.2. Immunization scheme of mice. 
 
 
2.9. Collection of blood samples 
 
 
2.9.1. Collection of blood samples by tail bleeding 
 
 
- warm the mouse by using infrared heat lamp  
- place the mouse on the top of the cage  
Mitterhumer Eva                                    Materials and Methods 
 55 
- hold the tail loosely above the collection tube 
- carve the vein using a scalpel  
- collect blood as long as drops appear 
- using sterile kitchen roll swab the wound and apply pressure to stop 
bleeding 
- allow clotting of blood for 3 h at RT 
- centrifuge for 10 min at 3,500 rpm 
- remove serum 
- use it immediately for analyzes or store at -20 °C  
 
 
2.9.2. Collection of blood samples by cardiac puncture 
 
 
When the subsequent experimental procedure permitted cardiac puncture 
(terminal method, not useful if the peritoneum needs to be lavaged), we used 
this method to collect large blood samples.  
 
- anesthetize mouse 
- lay the mouse on the back 
- take a syringe and penetrate the sternum into the heart 
- if blood does not emerge, try a different angle 
- gently pull back the plunger and collect blood sample 
- allow clotting of blood for 3 h at RT 
- centrifuge for 10 min at 3,500 rpm 
- remove serum 
- use it immediately for analyzes or store at -20 °C  
 
 
 
 
 
Mitterhumer Eva                                    Materials and Methods 
 56 
2.10. Determination of ovalbumin-specific mouse IgE 
 
 
The quantification of Ovalbumin specific mouse IgE was carried out by using 
Mouse Ovalbumin specific IgE ELISA ASSAY KIT (Serotec) according to the 
manufacturer’s protocol. We used BioTek ELx50 microplate washer to wash the 
ELISA plates. An ELISA reader (BenderMedSystems) was used to measure the 
absorbance at 450 nm (reference wavelength: 620 or 630 nm). Preparation of 
standard curve and reading of IgE concentration in the samples was performed 
by ELISA reader using point to point curve fit method (lin/lin).  
 
 
- keep reagents to RT 
- dilute wash buffer concentrate 10-fold with purified water 
- add 500 µl of purified water to standard A-F and let stand for 15 min 
- decant the contents of each well used 
- dispense 150 µl buffer into microplate for pre-dispensing samples  
- dispense 15 µl of sample or standard solution into this mircoplate 
- keep the plate 10 min at RT  
- dispense 110 µl of the diluted sample or standard into the pre-coated 
wells  
- agitate the plate and incubate the plate covered with aluminum foil for 
60 min at RT 
- wash the plate three times with wash buffer, 300 µl for each well 
- add 100 µl of antibody-enzyme conjugate 
- agitate the plate and incubate the plate covered with aluminum foil for 
30 min at RT 
- wash the plate three times with wash buffer, 300 µl for each well 
- add 100 µl of substrate  
- agitate the plate and incubate the plate covered with aluminum foil for 
30 min at RT 
- add 100 µl of stop solution  
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- measure the absorbance at 450 nm (reference wavelength: 620 or 
630 nm) 
- preparation of standard curve and reading of IgE concentration in the 
samples was performed  
 
 
2.11. Adoptive Transfer of CFSE-labelled T cells 
 
 
To study in vivo T cell responses in mice, we performed adoptive transfer of 
CFSE-labelled T cells. T cells were purified as described under “Isolation of 
CD4+ T cells” and labelled with CFSE as described under point 2.13. 
 
 
- wash cells twice with PBS and resuspend the cell pellet in PBS (5 x 
106 CFSE-labelled T cells / 200 µl / mouse) 
- put the mouse in an animal restraint which allow tail exposure 
- warm mouse tail in hand-hot water for 3-5 min 
- allow T cell solution to warm to RT 
- prepare syringe with a 30 gauge needle  
- draw up the T cell solution 
- insert the needle into the tail vein 
- dispense 200 µl (5 x 106 CFSE-labelled T cells) into the vein 
- return the mouse into the cage 
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2.12.  Preparation of animals  
 
 
Mice were killed by cervical dislocation. Before peritoneal wall incision, the 
abdomen was disinfected with 70 % ethanol. All organs were removed under 
sterile conditions. 
 
 
2.12.1. Removal of spleen  
 
 
2.12.1.1.  Dissection of the spleen only 
 
- place the mouse on its right side 
- cut the skin and the muscle layer above the spleen and liver 
- hold the spleen with a forceps 
- remove the spleen from attached organs 
- place the spleen in a PBS-containing tube 
 
 
 
Fig. 2.3. Removal of the spleen. 
spleen 
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2.12.1.2. Dissection of the spleen if  further organs are needed 
 
- fix the mouse  
- cut the skin and the muscle layer along the median axis 
- the spleen is located on the left side of the mouse, next to the left 
lobe of the liver 
- take the spleen with a forceps 
- remove the spleen from attached organs 
- place the spleen in a PBS-containing tube 
- proceed to the dissection of further needed organs  
 
 
 
Fig. 2.4. Removal of the spleen if you need further organs.  
spleen 
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2.12.2. Removal of mesenteric and inguinal lymph nodes 
 
 
- fix the mouse  
- cut the skin and the muscle layer along the median axis 
- identify inguinal lymph nodes 
- take the lymph nodes with a forceps  
- pull the lymph node out of the attached tissue 
- place the lymph nodes in a PBS-containing tube 
- take the blind gut and place it to the right side next to the foot 
- take the intestinal loops and place them to the right side 
- identify mesenteric lymph nodes 
- take the lymph nodes with a forceps  
- pull the lymph node out of the attached tissue 
- place the lymph nodes in a PBS-containing tube 
- as control: lymph nodes go down in contrast to fat tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5. Removal of lymph nodes. (a) Removal of inguinal lymph nodes. (b) Removal of 
mesenteric lymph nodes.  
a b 
inguinal LN mesenteric LN 
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2.12.3. Removal of lung 
 
 
- open the rib cage 
- remove the whole thoracic organs by intersecting the esophagus, 
vena cava and thoracic aorta 
- hold the lung with a forceps 
- cut the attachment under the lung towards the neck  
- remove the whole thoracic organs 
- remove the lung from the remaining organs  
 
 
 
Fig. 2.6. Removal of the lung.  
heart 
lung 
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2.12.4. Removal of the intestine 
 
 
- fix the mouse  
- cut the skin and the muscle layer along the median axis 
- take the intestinal loops and cut the intestine directly below the 
stomach and above the rectum 
- the blind gut is located between the small intestine and the ascending 
colon 
- free the intestines from any fatty tissue 
- defecate the intestine 
- flush the intestine with PBS carefully using a syringe 
 
 
2.12.5. Removal of the liver 
 
 
- fix the mouse  
- cut the skin and the muscle layer along the median axis 
- the liver is located below the sternum 
- take the liver with a forceps 
- remove the liver from attached organs 
- place the liver in a PBS-containing tube 
 
 
2.12.6. Removal of the kidneys 
 
 
- fix the mouse  
- cut the skin and the muscle layer along the median axis 
- the kidneys is located on the dorsal wall of the abdominal cavity 
- take the kidneys with a forceps carefully (don’t damage!) 
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- remove the kidney  
- place the kidneys in a PBS-containing tube 
 
 
2.12.7. Removal of the brain 
 
 
- cut off the head 
- remove excess tissue using a forceps until you be able to see the 
cerebellum 
- cut the skullcap sagittal using a scissor  
- remove the skullcap by breaking off small pieces with a forceps 
- avoid injuring to the brain 
- turn the head upside down 
- carefully remove structures anchoring the brain  
- take off the brain  
- place the brain in a PBS-containing tube 
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2.13. Cell preparation  
 
 
2.13.1. Splenic single cell suspension 
 
 
- place isolated spleens in a well of a 6-well plate with 5 ml collagenase 
D (1 mg/ml, Roche Applied Science) 
- flush the spleen with collagenase D using a 1 ml syringe 
- cut the tissue in small pieces 
- incubate for 40 min at 37 °C 
- apply the whole material on a 40 µm pore-size cell strainer placed on 
a 50 ml tube 
- squeeze the whole material through the cell strainer by gentle 
agitation with the top part of the pestle of a small syringe  
- flush the strainer frequently during this process with chilled washing 
medium 
- wash cells with chilled PBS 
- resuspend the cell pellet in 5 ml erythrocyte lysis buffer 
- incubate for 5 min at RT 
- stop the lysis by addition of approximately 30 ml washing medium 
- wash cells with chilled PBS 
- resuspend the cell pellet in PBS or appropriate medium depending on 
further procedure 
 
 
2.13.2. Lymph node and lung single cell suspension 
 
 
- place isolated lymph nodes or lung on a 40 µm pore-size cell strainer 
placed on a 50 ml tube 
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- squeeze the lymph nodes / tissue through the cell strainer by gentle 
agitation with the top part of the pestle of a small syringe  
- flush the strainer frequently during this process with chilled washing 
medium 
- wash cells with chilled PBS 
- resuspend the cell pellet in PBS or appropriate medium depending on 
further procedure 
 
 
2.14.  Immunomagnetic cell purification 
 
 
2.14.1. General materials 
 
 
MS, LS, and CS separation columns, magnetic separator (all from Miltenyi 
Biotec) 
 
 
2.14.2. Isolation of CD11c+ cells  
 
 
2.14.2.1. Isolation of splenic CD11c+ cells  
 
 
- wash spleen cells twice with chilled PBS 
- resuspend the cell pellet in MACS buffer (400 µl / 108 cells) 
- add 100 µl of CD11c MicroBeads per 108 total cells 
- mix well and incubate for 15 min at 4 – 8°C 
- wash cells with 30 ml MACS buffer 
- resuspend the cell pellet in 500 µl MACS buffer per 108 cells 
- choose column size depending on the cell number 
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- place the column in the magnetic separator 
- rinse the column with MACS buffer (volume depending on the column 
size) 
- apply cells onto the column 
- flush the column thrice with the appropriate amount of MACS buffer 
(depending on the column size) 
- remove column from the separator 
- place the column on a 14 ml polypropylene tube (Falcon) 
- apply 4 ml washing medium onto the column 
- flush out fraction with the magnetically labelled cells by applying the 
plunger supplied with the column 
- wash the cells 
- resuspend 2 x 105 cells in 100 µl PBS 
- preincubate the cells with rat and hamster serum for at least 15 min on 
ice 
- add PE-labelled hamster anti-mouse CD11c and PE-Cy5.5-labelled rat 
anti-mouse CD19 (5 µg/ml each)  
- mix well and incubate for 30 min on ice 
- wash cells twice 
- sort cells for CD11c+ and CD19- 
 
 
2.14.2.2. Isolation of CD11c+ lung cells  
 
 
- wash the cells 
- resuspend 2 x 105 cells in 100 µl PBS 
- preincubate the cells with rat and hamster serum for at least 15 min on 
ice 
- add APC-Alexa Fluor 750-labelled hamster anti-mouse CD11c (5 
µg/ml) and APC-labelled rat anti-mouse CD45 (1 µg/ml) 
- mix well and incubate for 30 min on ice 
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- wash cells twice 
- sort cells for CD11c+ and CD45+ 
 
 
2.14.3. Isolation of CD4+ T cells  
 
 
- wash spleen cells twice with chilled PBS 
- resuspend cell pellet in chilled PBS (30 x 106 /ml) 
- label cells by addition of biotinylated mAbs: anti-CD11c, anti-CD19, 
anti-B220, anti-GR-1, anti-TER, anti-CD11b, anti-CD8 and anti-NK-1.1 
(2 µg/ml each) 
- mix well and incubate for 30 min on ice 
- wash cells twice with chilled PBS 
- resuspend the cell pellet in 80 µl MACS buffer per 107 cells 
- add 20 µl of MACS anti-Biotin MicroBeads per 107 cells  
-  mix well and incubate for 15 min at 4 – 8°C 
- wash cells with 30 ml MACS buffer 
- choose column size depending on the cell number 
- prepare the column following the instructions of the manufacturer  
- apply cells onto the column and collect non-retained cells 
- flush the column thrice with the appropriate amount of MACS buffer 
(depending on the column size) 
- wash the cells 
 
 
2.15. Flow cytometry analysis 
 
 
Three-color FACS-analysis was performed on a FACScan, six-color analysis on 
a FACSAria (Both from BD Biosciences, San Jose, CA). Antibodies were used at 
the concentrations indicated by the manufacturers. If directly labelled antibodies 
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were used, non-specific binding of antibodies was prevented by blocking with 
10% rat serum and/or with 10% hamster serum depending on the host species 
used for antibody production.  
 
 
2.15.1. General protocol of direct labelling 
 
 
- wash cells twice in chilled PBS 
- resuspend 2 x 105 cells in 100 µl PBS 
- preincubate the cells with animal serum for 15 min on ice 
- add fluorochrome-conjugated mAbs at the concentration indicated by 
the manufacturer 
- mix well and incubate for 30 min on ice 
- wash cells twice 
- resuspend cells in 100 µl PBS 
- analyze cell on a flow cytometer 
 
 
2.15.2. General protocol of indirect labelling 
 
 
- wash cells twice in chilled PBS 
- resuspend 2 x 105 cells in 100 µl PBS 
- add biotin-conjugated mAbs at the concentration indicated by the 
manufacturer 
- mix well and incubate for 30 min on ice 
- wash cells twice 
- add appropriate second step antibody at the indicated concentration 
- incubate for 25 min on ice 
- wash cells twice with PBS 
- resuspend cells in 100 µl PBS 
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- analyze cells on a flow cytometer 
 
 
2.15.3. Fluorescence-activated cell sorting 
 
 
Cell sorting was carried out on a FACSAria flow cytometer (BD Biosciences). 
 
- stain cells according to the general protocol of direct / indirect 
labelling 
- wash cells with chilled PBS 
- resuspend the cell pellet in washing medium (10 x 106 /ml) 
- filter cells through a 40 µm pore-size cell strainer 
- sort the cells of interest into polystyrene tubes that have been rinsed 
with washing medium 
 
 
2.16. CFSE labelling  
 
 
- solve CFSE in DMSO at 10 mM 
- purify cells of interest, wash twice in cold PBS 
- dilute CFSE in PBS to 1 µM for in vitro T cell stimulation and to 5 µM 
for adoptive transfer of T cells 
- resuspend the cell pellet in CFSE solution (1 ml/107 cells) 
- mix well and incubate for 10 min at RT 
- stop labelling by addition of 1 volume FCS 
- wash cells twice with PBS supplemented with 10 % FCS 
- control CFSE labelling by FACS analysis 
- for adoptive transfer wash cells twice with PBS and resuspend the cell 
pellet in PBS 
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- for in vitro T cell stimulation wash cells twice with washing medium and 
resuspend cell pellet in appropriate culture medium 
 
 
2.17.  Stimulation of T cell proliferation 
 
 
- incubate 3x104 CD11c+ DCs with 6x105 Ova-specific DO11.10 T cells 
in a total of 200 µl culture medium for proliferation assays in a 96-well 
round-bottom plate; culture medium for proliferation assays was used 
for background control. Conditions are tested in triplicates.  
- pulse cells with defined concentrations of Ova protein or 4-hydroxy-3-
nitrophenylacetyl hapten- (NP-) conjugated Ova protein 
- if required, add chimeric IgE anti-NP 
- incubate the plates for 72 h at 37 °C and 5 % CO 2 and 95 % relative 
humidity  
- take off 100 µl supernatant for cytokine determination 
- add 1 µCi of [methyl-3H]thymidine (GE Healthcare) per well 
- incubate the plates for 18h at 37 °C and 5 % CO 2 and 95 % relative 
humidity  
- determine 3H-thymidine-uptake using a Wallac 1205 Betaplate Liquid 
Scintillation counter 
 
 
2.18.  Determination of 3H-thymidine-uptake 
 
 
- harvest 96-well round-bottom plate using a Harvester 96 Mach II on a 
pre-wet glass fibre filter according to the manufacturer’s protocol 
- dry the filter for 45 sec at 600 W in a microwave 
- melt-on scintillator sheet on the top of the filter in a sample bag for 1 
min using a T-Tray Heatsealer 
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- measure 3H-thymidine-uptake using a Wallac 1205 Betaplate Liquid 
Scintillation counter according to the manufacturer’s protocol 
 
 
2.19.  Cytokine measurement in cell culture supernatants 
 
 
The quantification of mouse IL-2, IL-4, IL-5, IFN-γ and TNF was carried out by 
using the Mouse Th1/Th2 Cytokine CBA (BD Biosciences) according to the 
manufactureres protocol. Samples were acquired on a FACScan using BD 
CellQuest Software and BD CBA Multiplex Template. Analysis of CBA data was 
performed using BD Cytometric Bead Array Analysis.  
 
 
2.19.1. Preparation of samples  
 
 
- reconstitute 1 vial of lyophilized Mouse Th1/TH2 Cytokine Standard 
with 0.2 ml of Assay Diluent; allow the standard to equilibrate for at 
least 15 min 
- prepare the top standard by addition of 100 µl of 10x bulk standard to 
900 µl assay diluent 
- perform a 1:2 serial dilution coming up to a 1:256 dilution 
- mix 10 µl of each vortexed capture bead for each assay tube (= 
mixed capture beads) 
- add 50 µl of the mixed capture beads to the assay and control tubes 
- add 50 µl of the Mouse Th1/Th2 Cytokine Standard dilution to the 
control tubes 
- add 50 µl of each sample to the assay tube 
- add 50 µl of the Mouse Th1/Th2 PE Detection Reagent to each tube 
- mix well 
- incubate for 2 h at RT and protect from light 
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- add 1 ml of Wash Buffer  
- centrifuge for 5 min at 1600 rpm 
- aspirate the supernatant 
- add 300 µl Wash Buffer to each tube and resuspend the pellet 
- analyze sample on the flow cytometer 
 
 
2.19.2. Cytometer setup 
 
 
BD CBA instrument Setup template was used for cytometer setup 
 
- add 50 µl of Setup Beads to three setup tubes labelled A, B and C 
- add 50 µl of FITC Positive Control to tube B 
- add 50 µl of PE Positive Control to tube C 
- incubate for 45 min and protect from light 
- add 450 µl Wash Buffer to tube A and 400 µl of Wash Buffer to tubes 
B and C 
- follow the instructions of BD CBA set up template 
 
 
2.20.  Immunohistochemistry 
 
 
2.20.1. General Immunohistochemistry 
 
 
- dissect tissues and mount in OCT 
- freeze in liquid nitrogen and store at -20°C 
- cut 7 µm sections on a cryomicrotome 
- fix sections in acetone for 10 min on ice 
- incubate in 2 % BSA / PBS for 10 min 
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- block with 0.3 % H2O2 for 20 min 
- block non-specific antibody binding with 2 % mouse serum in 2 % 
BSA / PBS 
- overlay sections with biotinylated primary antibody (anti-huFcεRIα 
mAb 15-1-biotin or cIgE-biotin) diluted in 2 % BSA / PBS for 1 h at RT 
- wash 5 times with PBS 
- overlay sections with the detection enzyme (SA-HRP) diluted in 2 % 
BSA / PBS for 40 min at RT 
- wash 5 times with PBS 
- cover the sections with AEC substrate chromogen (approximately 2 
drops) 
- incubate for 5 min at RT 
- wash 5 times with PBS 
- counter stain with filtered haematoxylin for 10 sec 
- wash 5 times with water 
- mount in aqueous mounting medium 
 
 
2.20.2. Immunofluorescence 
 
 
- dissect tissues and incubate organs 4.5 h in 5 % formalin  
- mount in OCT 
- freeze in liquid nitrogen and store at -20 °C 
- cut 7 µm sections on a cyromicrotom 
- wash sections with PBS 
- mount in VectaShield Mounting medium 
- examine sections using a LSM 520 confocal microscope (Zeiss) 
- record fluorescence light emission of 505-550 nm (green) and 560-
615 (red) 
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2.20.3. Scoring of H&E-stained lung sections 
 
 
Lungs were removed, fixed in buffered formaldehyde and embedded in paraffin. 
The morphological signs of LAR severity were ascertained by Dr. Antal Rot, 
Novartis Institutes for BioMedical Research, Vienna under the microscope in 5 
µm H&E stained sections. 
 
 
2.21.  Protein quantification 
 
 
We used BCA Protein Assay Kit (Pierce) to quantify protein concentrations.  
 
- prepare a dilution series of BSA protein (2,000 µg/ml – 25 µg/ml) 
using the same buffer in which the protein of interest is dissolved 
- prepare working reagent: mix 50 parts of BCA reagent A with 1 part of 
BCA reagent B  
- add 100 µl of each standard and unknown sample into a disposable 
plastic cuvette 
- add 2 ml working reagent to each cuvette 
- mix well 
- incubate for 30 min at 60 °C 
- cool all cuvettes to RT 
- measure absorbance at 562 nm in a spectrophotometer 
- subtract the blank absorbance from sample and standard 
absorbances 
- draw a standard curve by plotting absorbance at 562 nm for each 
BSA standard versus its concentration in µg/ml 
- interpolate the concentration of unknown samples using a linear 
regression line 
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2.22. List of reagents 
 
 
2.22.1. Antibodies 
 
 
2.22.1.1. Antibodies for immunomagnetic depletion 
 
 
Specificity Clone Conjugate Manufacturer Cat# 
     CD8a 53-6.7 Biotin eBiosciences 13-0081 
CD11b M1/70 Biotin BD Biosciences 553309 
CD11c HL3 Biotin BD Biosciences 553800 
CD19  1D3 Biotin BD Biosciences 553784 
B220 RA3-6B2 Biotin BD Biosciences 553086 
Gr-1 RB6-8C5 Biotin BD Biosciences 553125 
NK1.1 PK136 Biotin eBiosciences 13-5941 
TER-119 TER-119 Biotin BD Biosciences 553672 
 
 
2.22.1.2. Antibodies for cell characterization  
 
 
Specificity Clone Conjugate Manufacturer Cat# 
     CD3 
Molecular 
Complex 
17A2 Purified  BD Biosciences 555273 
CD3 
Molecular 
Complex 
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Specificity Clone Conjugate Manufacturer Cat# 
     CD3e 145-2C11 APC BD Biosciences 553066  
CD3e 17A2 APC-Alexa Fluor 
750 
eBioscience 27-0032 
CD4 H129.19 PE-Cy5 BD Biosciences 553654 
CD4 L3T4 PerCP BD Biosciences 553052  
CD4 H129.19 PE-Cy5 BD Biosciences 553654 
CD8a 53-6.7 PerCP BD Biosciences 553036 
CD8a 53-6.7 APC BD Biosciences  553035 
CD8a 53-6.7 PE-Cy7 eBioscience 25-0081 
CD11c HL3 PE BD Biosiences 553802 
CD11c HL3 APC eBioscience 550261 
CD11c N418 APC-Alexa Fluor 
750 
eBioscience 27-0114 
CD11b 3A33 PE-Cy7 Abcam ab25506 
CD19 6D5 PE-Cy5.5 Abcam ab25548 
CD19 6D5 PE-Cy7 Abcam ab25509 
CD40 3/23 PE BD Biosciences 553791 
CD45 30-F11 APC BD Biosciences 559864 
CD80 16-10A1 PE BD Biosciences 553769 
CD86 GL1 PE BD Biosciences 553692 
B220 RA3-6B2 PE BD Biosciences 553090 
B220 RA3-6B2 PerCP BD Biosciences 553093 
DO11.10 TCR KJI-26 PE BD Biosciences 551772 
F4/80 BM8 PE eBioscience 12-4801 
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Specificity Clone Conjugate Manufacturer Cat# 
     GR-1 RB6-8C5 PerCP-Cy5.5 BD Biosciences 552093 
human 
FceRIα 
Cra1 Purified eBioscience 16-5899 
human 
FceRIα 
Cra1 Biotin eBioscience 13-5899 
human 
FceRIα 
Cra1 PE eBioscience 12-5899 
human 
FceRIα 
Cra1 APC eBioscience 17-5899 
human IgE B3102E8 Biotin SouthernBiotech 9160-08 
mouse IgE R35-72 Biotin BD Biosciences 553414 
mouse IgE 23G3 Biotin SouthernBiotech 1130-08 
mPDCA JF05-
1C2.4.1 
PE Milteny Biotec 130-091-
962 
MHC Class II  M5/114.15.2 PE BD Biosciences 557000 
MHC Class II  M5/114.15.2 PE-Cy5 eBioscience 15-5321 
 
 
2.22.1.3. Antibodies against chemokine receptors 
 
 
Specificity Clone Conjugate Manufacturer Cat# 
     CCR3 83101  PE R&D FAB729P 
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2.22.1.4. Other antibodies  
 
 
Specificity Description Clone Conjugate Manufacturer Cat# 
     NP chimeric 
human IgE 
JW8/1 Purified Serotec MCA333B 
Ovalbumin mouse IgE 2C6 Purified Serotec MCA2259 
Ovalbumin mouse IgE  Purified Serotec PMP68 
Ovalbumin mouse IgE C38-2 Purified BD Biosciences 557079 
 
 
2.22.1.5.  Isotype controls 
 
 
Host species Isotype Conjugate Manufacturer Cat# 
     Mouse IgG1 Purified Simga-Aldrich M9269 
Mouse IgG2a Purified Simga-Aldrich M9144 
Mouse IgG2b Purified Simga-Aldrich M8894 
Rat IgG1 PE BD Biosciences 553925 
Rat IgG1 APC BD Biosciences 550884 
Rat IgG1 PE-Cy7 BD Biosciences 557645 
Rat IgG2a PE BD Biosciences 553930 
Rat IgG2a PerCP BD Biosciences 553933 
Rat IgG2a APC BD Biosciences 554690 
Rat IgG2a PE-Cy7 BD Biosciences 552784 
Rat IgG2b PE BD Biosciences 553989 
Rat IgG2b APC BioLegend 400612 
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Host species Isotype Conjugate Manufacturer Cat# 
     Rat IgM PE-Cy7 SouthernBiotech 0120-17 
Hamster IgG1 PE BD Biosciences 553954 
Hamster IgG1 APC BD Biosciences 553956 
Hamster IgG1 APC-Alexa Fluor 750 eBiosciences 27-4888 
 
 
2.22.1.6. Second-step reagents 
 
 
Reagent Abbreviation Conjugate Manufacturer Cat# 
     Streptavidin SA-PE PE BD Biosciences 349023 
Streptavidin SA-APC APC BD Biosciences 349024 
 
 
2.22.2. Peptides and proteins 
 
 
Protein/Peptide Abbreviation Conjugate Manufacturer Cat# 
     Bovine Serum 
Albumin Grade 
5 
BSA  Sigma-Aldrich A2153 
Bovine Serum 
Albumin 
NP-BSA 4-Hydroxy-3-
nitrophenylacetyl 
Biosearch 
Technologies 
N-5050-10 
Ovalbumin 
Grade V 
Ova  Sigma-Aldrich A5503 
Ovalbumin 
Grade V 
NP-Ova 4-Hydroxy-3-
nitrophenylacetyl 
Biosearch 
Technologies 
N-5051-10 
SIINFEKL (Ova 
257 – 264) 
pOva  Anaspec 60193-5 
 
Mitterhumer Eva                                    Materials and Methods 
 80 
2.22.3. General reagents 
 
 
Reagent Abbreviation Manufacturer Cat# 
     4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
HEPES GIBCO BRL 15630-049 
4-Hydroxy-3-
nitrophenylacetyl hapten-PE
NP-PE Biosearch 
Technologies 
N-5070-1 
5(6)-Carboxyfluorescein 
diacetate N-Succinimidyl 
ester 
 Sigma-Aldrich 21888-25MG-F 
β-Mercaptoethanol    
Acetone  Merck 8.22251.2500 
Aluminum hydroxide alum Serva  12261.01  
Anti-Biotin MicroBeads  Miltenyi Biotec 130-090-485 
Biotin – X – NHS  Calbiochem 203188 
CD11c MicroBeads  Miltenyi Biotec 130-052-001 
CD Hybridoma Medium  Invitrogen VX11279023 
Collagenase D  Roche 11088866001 
Dimethylsulfoxide DMSO MERCK 1.09678 
Ethanol, 96% EtOH Pharmacy, AKH 58601 
Foetal calf serum (heat 
inactivated) 
FCS Invitrogen 10500-064 
Formaldehyde 7.5%  SAV Liquid 
Products  
N-29401 
Geneticin G-418 Sulphate  GIBCO BRL 11811-023 
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Reagent Abbreviation Manufacturer Cat# 
     Goat serum  Sigma-Aldrich G9023 
Hamster serum  Jackson Immuno 
Research 
007-000-120 
Human IgE, myeloma  Calbiochem 401152 
Ionomycin Iono Sigma-Aldrich I0634 
Iscove´s modified 
Dulbecco´s medium 
IMDM GIBCO BRL 21980-032 
L-glutamine  GIBCO BRL 25030-024 
Mouse serum  Chemicon S25-10ml 
Non-essential amino acids, 
100x 
NEA Biochrom AG K0293 
NaCl  MERCK 106.404 
NaOH  MERCK 106.498 
O.C.T.  Sakura 4583 
ODN 2395 CpG Alexis 
Biochemicals 
ALX-746-020-
T100 
Penicilin/streptomycin PenStrep GIBCO BRL 15140-114 
Phorbol 12-myristate 13-
acetate  
PMA Sigma-Aldrich P8139 
Phosphate-buffered saline PBS GIBCO BRL 14190-094 
Rat IgG  Simga-Aldrich I4131 
Rat serum  PAA B02037 
RPMI 1640  GIBCO BRL 52400-025 
Sodium pyruvate, 100x  GIBCO BRL 11360-039 
Trypsin-EDTA, 0.05%  GIBCO BRL 25300-054 
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Reagent Abbreviation Manufacturer Cat# 
     VectaShield Mounting 
medium 
 Vector Labs H-1000 
Water, double distilled ddH2O Fresenius Kabi 11500293 
 
 
2.22.4. Used commercial kits 
 
 
- BCA Protein Assay Kit, Pierce 
- BCA Reagent A 
- BCA Reagent B 
- Albumin Standard Ampules 
 
 
- Mouse Ovalbumin specific IgE ELISA ASSAY KIT 
- Standard A (lyophilized) 
- Standard B (lyophilized) 
- Standard C (lyophilized) 
- Standard D (lyophilized) 
- Standard E (lyophilized) 
- Standard F (lyophilized) 
- Buffer 
- Detection conjugate 
- Antibody-coated assay plate 
- Wash buffer concentrate 
- Substrate 
- Stop solution 
- Microplate for predispensing samples 
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- Mouse Th1/Th2 Cytokine CBA 
- Mouse IL-2 Capture Bead 
- Mouse IL-4 Capture Bead 
- Mouse IL-5 Capture Bead 
- Mouse IFN-γ Capture Bead 
- Mouse TNF Capture Bead 
- Mouse Th1/Th2 PE Detection Reagent 
- Mouse Th1/Th2 Cytokine Standards 
- Cytometer Setup Beads 
- PE Positive Control Detector 
- FITC Positive Control Detector 
- Wash Buffer 
- Assay Diluent 
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3. Results 
 
 
3.1. Transgenic mice with FcεRI expression on dendritic 
cells 
 
 
Murine DCs, in contrast to human DCs do not express FcεRI constitutively. As 
described under point 1.5 (α-DC transgenic mice: the tool of my study), our 
laboratory created α-DC TG mice harboring a germ line-integrated construct 
expressing the human IgE-binding FcεRIα-chain and eGFP under control of the 
DC-restricted, constitutively active CD11c promoter (Fig 1.14).  
 
To study FcεRI surface expression and eGFP expression in vitro, HEK cells 
were transfected either with a mock construct or the construct containing the 
human α-chain gene and eGFP. We could determine only eGFP expression but 
no receptor surface expression after vector transfection. However, co-
transfection of this construct with a vector harboring the murine FcεRIγ-chain 
gene – in vivo provided by DCs themselves – revealed green fluorescent 
transfectants expressing a huαmuγFcεRI receptor on their surface as revealed 
by murine IgE binding and anti-FcεRIα immunoreactivity (Fig. 3.1).  
 
The fact that in our model huFcεRIα surface expression requires co-expression 
of the myeloid-restricted murine FcεRIγ (19, Fig. 3.1) contributes to DC-
restriction of FcεRIα expression in a transgenic promoter-independent fashion. 
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Transfection with 
human 
FcεRIα-GFP 
human FcεRIα-GFP  
+ murine FcεRIγ 
Ab reactivity 
mock 
anti- 
huFcεRIα 
murine 
IgE 
control 
eG
FP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 1. Murine γ-chain revealed surface expression of huFcεRIα. Facs analysis of mock 
(left), huFcεRIα (middle) and huFcεRIαmuFcεRIγ transfected HEK 293 T cells. T cells were 
stained with either control antibody (first panel), 15-1 antibody (anti-FcεRIα; second panel) or 
bound with murine IgE (last panel).  
 
 
To analyze DC-restricted transgen expression in various tissues of α-DC TG 
mice, we measured eGFP expression by FACS analysis. In α-DC TG mice, 
discrete populations of eGFP-expressing cells were detected in lymphoid 
(spleen, lymph nodes) and non-lymphoid organs (e.g., lung, intestine, liver; Fig. 
3.2). 1.1% (spleen), 0.9% (lymph nodes), 0.1% (lung), 0.02% (intestine), 0.01% 
(liver), 0.1% (kidney) and 0.0% (brain) of total cells expressed eGFP (Fig. 3.2). 
eGFP+ cells in the various organs were DCs as shown by their high MHC class 
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WT 
eGFP 
α-DC TG 
lymph  
node 
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spleen 
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liver 
brain 
1.1% 
0.9% 
0.1% 
0.02% 
0.01% 
0.0% 
kidney 0.1% 
M
H
CI
I
II expression, display of co-stimulatory molecules, and superior T cell 
stimulatory capacity (Fig. 3.2, 3.3, 3.5). Binding of monomeric IgE to FcεRI-
expressed DCs does not alter the expression level of co-stimulatory molecules 
and antigen presentation capacity (Fig. 3.3, 3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 2. DCs from lymphoid organs as well as from non-lymphoid organs express 
human FcεRIα. Multi-organ double immunofluorescence analysis of eGFP (horizontal) and 
MHC class II expression (vertical) in WT (left panels) and α-DC TG mice (right panels). Cells 
shown were gated for CD45 expression. Panels (from top panel): spleen, lymph node, lung, 
intestine, liver, kidney and brain.  
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Fig. 3.3. Expression of co-stimulatory molecules on DCs from α-DC TG mice is not 
altered in the presence of IgE. Demonstration of CD86 (left panel), CD80 (middle panel) and 
MHC class II expression (right panel) in eGFP+ FcεRIα+ splenocytes. Cells were incubated in 
the presence (red) or the absence (purple) of IgE. Black histograms denote the reactivity of 
isotype-matched control mAbs. Experiment was performed in collaboration with E. Fiebiger. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 4. Binding of monomeric IgE does not alter antigen presentation capacity. DCs 
isolated from α-DC TG (closed squares) and WT mice (open circles) were cultured with naïve 
Ova-specific DO11.10 T cells in the presence of graded concentrations of Ova peptide 
(Ova323-339; ISQAVHAAHAEINEAGR) in absence (left) or presence (right) of antigen-
unspecific IgE. 3H-thymidine uptake was measured (mean cpm of triplicate cultures + s.e.m.; 
vertical). 
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Fig. 3. 5. DCs from α-DC TG mice present exogenously added peptide to T cells at the 
same efficacy as DCs from WT mice. Sorted splenic CD11c+ DCs from α-DC TG (closed 
squares) and WT mice (open circles) and, for control purposes, CD19+ B cells from α-DC TG 
(closed triangles) and WT mice (open diamonds) were assayed for presentation of a synthetic 
Ova peptide (Ova323-339; ISQAVHAAHAEINEAGR). 3H-thymidine uptake of Ova-specific T 
cells (cpm; vertical) in response to graded concentrations of Ova peptide (horizontal) was 
measured. Mean cpm (+ s.e.m.) of triplicate cultures are shown. 
 
 
Gating for splenic CD11c+ DCs further revealed that the vast majority of all DCs 
expressed eGFP (Fig. 3.6, Fig 3.7). FcεRIα-chain surface expression was 
largely restricted to eGFP+ DCs as shown by anti-huFcεRIα immunoreactivity 
(Fig. 3.6, Fig. 3.7). The vast majority of CD11c+ DCs from both C57BL/6 and 
BALB/c mice expressed eGFP and human FcεRIα at comparable frequencies 
(Fig. 3.6, Fig. 3.7).  
 
Importantly, DCs from α-DC TG mice bound human as well as murine IgE in 
cell suspensions and on tissue sections (Fig. 3.8; Fig. 3.9) showing transgenic 
receptor expression in a functional configuration. Using immunohistochemistry 
we determined the distribution of transgene-expressing DCs in the spleen. We 
stained for human FcεRIα-expressing cells and showed that perifollicular IgE-
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binding, FcεRIα+ cells are detectable in α-DC TG mice but not in WT littermate 
controls (Fig. 3.8).  
In contrast, isolated and in situ DCs from WT mice did not bind IgE (Fig. 3.8; 
Fig. 3.9). Cellular characterization showed huFcεRIα expression on DCs but not 
on other cell types from α-DC TG mice like T cells, B cells, mast cells and 
basophils (Fig. 3.10, Fig 3.11).  
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Fig. 3. 6. Demonstration of huFcεRIα and eGFP expression in splenic CD11c+ cells from 
C57BL/6 mice by flow cytometry. Upper left panel: Gating of DCs from dot plots showing 
CD11c expression (horizontal) versus 90° light scat tering (SSC, vertical). Upper right panel: 
anti-huFcεRIα immunoreactivity of CD11c+ cells from WT (gray histogram) and α-DC TG mice 
(red histogram). Lower panels: dot plots showing eGFP (vertical) versus huFcεRIα expression 
(horizontal) in CD11c+ cells from WT (left) and α-DC TG mice (right). Experiment was 
performed in collaboration with E. Fiebiger. 
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Fig. 3. 7. Demonstration of huFcεRIα and eGFP expression in splenic CD11c+ cells from 
BALB/c mice by flow cytometry. Upper left panel: Gating of DCs from dot plots showing 
CD11c expression (horizontal) versus 90° light scat tering (SSC, vertical). Upper right panel: 
anti-huFcεRIα immunoreactivity of CD11c+ cells from WT (gray histogram) and α-DC TG mice 
(red histogram). Lower panels: dot plots showing eGFP (vertical) versus huFcεRIα expression 
(horizontal) in CD11c+ cells from WT (left) and α-DC TG mice (right). Experiment was 
performed in collaboration with E. Fiebiger. 
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      WT       α-DC TG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 8. FcεRI+ DCs are located in the T cell zones of lymphoid organs. Detection of 
huFcεRIα expression (upper panels) and human IgE binding (lower panels) on spleen sections 
from WT (left) and α-DC TG mice (right). HRP-based visualization of Ab-bound cells reveals 
huFcεRIα expression and IgE binding to perifollicular cells with dendritic morphology (insets, 
right panels); B, B cell follicle. 
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Fig. 3. 9. Transgenic CD11c+ DCs have the capability to bind human and murine IgE. 
Detection of human (upper panels) and murine IgE (lower panels) binding to isolated DCs from 
α-DC TG and WT mice (right and left panels, respectively) by anti-human and anti-murine IgE 
mAbs and flow cytometry (red histograms). Black histograms denote the reactivity of isotype-
matched control mAbs.  
 
 
 
 
Fig. 3. 10. CD11c+ DCs but not B cells or T cells from α-DC TG mice express FcεRIα. 
Analysis of huFcεRIα expression in splenic DCs (left), B cells (middle) and T cells (right) of α-
DC TG mice. Lines in histograms denote the upper limit of the reactivity of isotype-matched 
control mAbs. 
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Fig. 3. 11. Mast cells and basophils do not express human FcεRIα. (a) Analysis of eGFP 
(left) and c-kit expression (right) in muFcεRIα+ mast cells (red) and huFcεRIα+ DCs (blue) by 
flow cytometry. (b) Analysis of huFcεRIα (left) and MHC class II expression (right) in 
muFcεRIα+c-kit- basophils (red) and CD11c+eGFP+ DCs (blue) by flow cytometry.  
 
 
FcεRI on human DCs is expressed as αγ2 trimer (12). To glean information on 
the structural composition of FcεRI expressed on murine transgenic DCs, FcεRI 
receptors were immunoprecipitated. In DCs, FcεRI was assembled as a trimeric 
complex containing a huFcεRIα-chain (approx. 50 kDa) and a muFcεRIγ dimer 
(approx. 20 kDa, Fig. 3.12) and lacked FcεRIβ (data not shown). Control 
precipitates (without initial IgE binding) displayed no reactivity with either anti-
human α-chain or anti-murine γ-chain antibody. Thus, chimeric FcεRI on DCs of 
TG mice has the same molecular subunit composition as FcεRI on human DCs 
(12). 
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Fig. 3. 12. Immunoprecipitation of FcεRI complexes composed of huFcεRIα and 
muFcεRIγ from DCs. NP-sepharose precipitates from IgE anti-NP-loaded (right lanes) and 
unloaded α-DC TG DCs (left lanes) were analyzed by anti-huFcεRIα (upper panel) and anti-
muFcεRIγ immunoblotting (lower panel). The co-precipitated 18 kDa moiety in the lower panel 
corresponds to dimers of muFcεRIγ. Experiment was performed in collaboration with E. Fiebiger 
 
 
In a next set of experiments, we studied the huFcεRIα expression pattern on 
different DC subtypes including myeloid (CD4+ CD11c+), lymphoid (CD8+ 
CD11c+) and plasmacytoid DCs (B220+, CD19-, CD11clow, mPDCA-1+). In 
analogy to their CD11c expression level, myeloid DCs from α-DC TG mice 
expressed the highest level of huFcεRIα (Fig. 3.13a) while lymphoid and 
plasmacytoid DCs were rather devoid of huFcεRIα expression (Fig. 3.13b), a 
pattern that matches FcεRI expression on DC subsets in humans (123). 
Myeloid, lymphoid and plasmacytoid DCs from wild-type controls showed no 
huFcεRIα immunoreactivity or IgE-binding ability (Fig. 3.13).  
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Fig. 3. 13. FcεRI expression on different α-DC subtypes. (a) CD4+ CD11c+ myeloid DCs 
from α-DC TG mice express FcεRI. Demonstration of huFcεRIα expression of subtypes of 
splenic CD11c+ cells from α-DC TG and WT mice (right and left panels, respectively) by flow 
cytometry. Top panels: dot plots showing CD4 (horizontal) versus CD8 expression (vertical). 
Middle panels: anti-huFcεRIα immunoreactivity of CD4+CD11c+ cells (red histograms). Bottom 
panels: anti-huFcεRIα immunoreactivity of CD8+CD11c+ cells (red histograms). Black 
histograms denote the reactivity of isotype-matched control mAbs. (b) Plasmacytoid DCs from 
α-DC TG mice do not express the high affinity IgE receptor. Analysis of huFcεRIα 
expression in splenic pDCs from α-DC TG and WT mice (right and left panels, respectively) by 
flow cytometry. Top panels: dot plots showing CD19 (horizontal) versus B220 expression 
(vertical). Middle panels: gated B220+CD19- cells (P1) were analyzed for mPDCA-1 (horizontal) 
versus CD11c expression (vertical). Lower panels: anti-huFcεRIα immunoreactivity of 
B220+CD19-CD11clow and mPDCA-1+ cells (red). Black histograms denote the reactivity of 
isotype-matched control mAbs.  
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FcεRI-mediated antigen uptake fluid phase antigen uptake 
Next, we asked wether DC-expressed FcεRI is functional. To address this, we 
tested whether DCs from α-DC TG mice are capable of FcεRI-dependent 
antigen uptake.  
Comparing fluid phase and FcεRI-dependent antigen uptake, we showed that 
DCs from α-DC TG mice, but not DCs from WT mice, internalized full protein 
antigens in an IgE-dependent fashion (Fig. 3.14). Fluid phase antigen uptake, in 
contrast, was identical in DCs from α-DC TG and WT mice (Fig. 3.14).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 14. FcεRI and IgE-mediated antigen uptake in DCs. DCs from α-DC TG (closed 
squares) and WT mice (open circles) were loaded with NP-Ova under conditions permitting 
FcεRI-mediated (left panel) or fluid phase antigen uptake (right panel). 3H-thymidine uptake of 
Ova-specific T cells (cpm; vertical) was used to measure uptake and presentation of NP-OVA 
by graded numbers of DCs (horizontal). For FcεRI-mediated antigen uptake CD11c+ DCs were 
loaded with IgE anti-NP ON before incubation with 1 mg NP-Ova /106 cells for 1 h on ice. DCs 
were washed three times and allowed to internalize and process IgE-bound antigen for 2 h at 
37°C. For fluid-phase antigen uptake, CD11c + DCs were pulsed with NP-OVA for 2 h at 37°C. 
Experiment was performed in collaboration with E. Fiebiger. 
 
 
To conclude, α-DC TG mice display a “human-like” expression pattern of 
functional FcεRI on their DCs and are therefore a unique model to study the 
functional role of DC-expressed FcεRI in vivo.  
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3.2. DCs use FcεRI and antigen-specific IgE to augment 
antigen-specific T cell responses in vivo 
 
 
The FcεRI-mediated IgE binding to DCs was studied in vivo in naïve mice and 
mice immunized with Ova under conditions promoting antigen-specific IgE 
responses. DCs from WT mice displayed no surface-bound IgE irrespective of 
whether the mice were immunized or were not immunized with Ova (Fig. 3.15) 
showing that endogenous IgE receptors are not up-regulated on WT DCs during 
a Th2-dominated immune response. B cells from WT mice had bound some IgE 
under non-immunized and, more so, under immunized conditions (Fig. 3.15) 
indicating that B cells are the major IgE binding APCs in normal WT mice. In 
contrast, DCs from α-DC TG mice showed in vivo IgE binding under baseline 
conditions and further 5-10-fold increased levels of surface-bound IgE following 
immunization (Fig. 3.15). In vivo IgE binding to DCs was at least one order of 
magnitude higher than IgE binding to B cells in α-DC TG mice. Thus, DCs are 
the essential IgE binding APCs in α-DC TG mice what corresponds to the 
situation in allergic humans (128).  
 
 
Fig. 3. 15. FcεRI-expressing DCs bind the highest amounts of IgE in vivo. Detection of IgE 
bound to DCs (left panels) and B cells (right panesl) from i.p. Ova-immunized (lower panels) 
and non-immunized (upper panels) WT and α-DC TG mice (left and right panels, respectively) 
by anti-murine IgE mAbs and flow cytometry. Vertical lines in histograms denote the upper cut-
off of the reactivity of isotype-matched control mAbs. 
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To study a potential impact of the IgE-FcεRI interaction on DCs for antigen-
specific T cell activation in vivo, α-DC TG and WT mice were immunized 
repeatedly. The spleen cells recovered were restimulated with Ova in vitro and 
the T cell proliferation was measured by 3H-thymidine uptake. As shown in Fig. 
3.16, antigen-specific splenocytes proliferation was enhanced in Ova-
immunized α-DC TG mice as compared to WT controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 16. Augmented antigen-specific splenocyte proliferation in α-DC TG mice. 
Splenocytes from naïve and Ova-immunized α-DC TG (black bars) and WT mice (white bars) 
were cultured in the presence or absence of Ova (20 µg/ml) and 3H-thymidine uptake was 
measured (mean cpm of triplicate cultures + s.e.m.; vertical). 
 
 
Next we asked if the IgE-bound DCs are the stimulatory principle of this 
enhanced T cell response.  
α-DC TG mice and WT littermate controls were immunized with Ova. Spleens 
were harvested and CD11c+ cells were FACS-purified. These DCs were used 
as stimulators of Ova-primed T cells. We show that IgE-bearing DCs from α-DC 
TG were far more potent stimulators of Ova-specific recall T cell activation than 
were IgE- DCs from WT controls (Fig. 3.17a). Moreover, a 50-fold lower antigen 
concentration was required to initiate T cell proliferation with IgE+ DCs from α-
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DC TG than with IgE- DCs from WT mice. This indicates a functionally relevant 
lower antigen threshold necessary for T cell activation in α-DC TG mice. 
Next, IgE-bearing DCs from α-DC TG were used as stimulators of T cells which 
had been purified from Ova-immunized α-DC TG and WT mice. As shown in 
Fig. 3.17b, the Ova-specific proliferation of T cells from α-DC TG mice was 
higher than the proliferation of T cells from WT mice. Thus, the Ova-specific 
memory T cell response established in vivo is greater in α-DC TG than in WT 
mice. 
 
       a     b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 17. (a) FcεRI+ DCs loaded with antigen-specific IgE following immunization in vivo 
are superior stimulators of antigen-specific memory T cell responses. Splenic DCs 
isolated from Ova immunized α-DC TG (black squares) and WT mice (white circles) were 
cultured with isolated T cells from Ova immunized mice in the presence of graded 
concentrations of Ova (horizontal). 3H-thymidine uptake was measured (mean cpm of triplicate 
cultures + s.e.m.; vertical). (b) Augmented in vivo antigen-specific T cell response in α-DC 
TG mice. T cells isolated from Ova immunized α-DC TG (black squares) and WT mice (white 
circles) were cultured with isolated DCs in the presence of graded concentrations of Ova 
(horizontal). 3H-thymidine uptake was measured (mean cpm of triplicate cultures + s.e.m.; 
vertical). 
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Next, we analyzed whether the interaction of IgE with FcεRI is responsible for 
the enhanced T cell response observed. To address this issue, we used IgE-
deficient (IgE-/-) mice and crossed them into the α-DC TG background. IgE-/-α-
DC TG, α-DC TG and WT mice were immunized and spleen cells recovered 
were restimulated with defined concentrations of Ova protein. IgE-/-α-DC TG 
mice had an Ova-specific T cell response that is greatly reduced in comparison 
to that of IgE-proficient α-DC TG mice, yet comparable to that of WT mice (Fig. 
3.18). Thus, we conclude that the binding of antigen-specific IgE to FcεRI on 
DCs in vivo resulted in the enhanced antigen-specific memory T cell response 
due to antigen targeting to DCs in an IgE and FcεRI-dependent fashion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 18. The augmented antigen-specific proliferative response in α-DC TG mice 
depends on the presence of IgE in vivo. Splenocytes from Ova-immunized α-DC TG (black 
sqaures), IgE-/- α-DC TG mice (gray triangles), and WT mice (white circles) were cultured in the 
presence of graded concentrations of Ova and 3H-thymidine uptake was measured (mean cpm; 
vertical). 
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3.3. FcεRI+ DCs efficiently prime naïve T cells for Th2 
development and amplify antigen-specific Th2 
responses in vivo 
 
 
IgE-FcεRI-dependent amplification of T cell responses in vivo can be explained 
by enforced T cell expansion at the memory cell level due to repetitive antigen 
exposure and accumulating antigen-specific IgE. Besides, the possibility exists 
that IgE-FcεRI interactions allow DCs to increase their ability to activate and 
recruit greater cell numbers of antigen-specific naïve T cells.  
 
To test this, purified DCs were used as stimulators of naïve and primed Ova-
specific TCR transgenic T cells (DO11.10) in the presence or the absence of 
haptenized (NP-) Ova and hapten- (NP-) specific IgE. DCs isolated from non-
immunized WT and α-DC TG mice induced the same amount of T cell 
proliferation (Fig. 3.19a). However, addition of antigen-specific IgE caused a 
much stronger CD4+ T cell proliferation (Fig. 3.19b) and TNFα and IL-2 cytokine 
production (Fig. 3.20) when FcεRI+ DCs are present in the cultures than in the 
absence of FcεRI. The T cell proliferation-promoting effect of IgE was clearly 
evident over almost the entire dose range of antigen tested, yet became 
gradually less explicit with increasing antigen concentrations probably due to 
the saturable nature of FcεRI-dependent antigen uptake.  
 
Mechanistically, we found that IgE-FcεRI-facilitated T cell proliferation occurs 
due to (i) an increased rate of naïve T cells entering the cell cycle (Fig. 3.21) 
and, for cells that have already entered cell cycle, (ii) an accelerated 
propagation through consecutive rounds of cell division (Fig. 3.22). Interestingly, 
the proliferation-inducing effect of IgE-FcεRI-dependent antigen presentation 
was more critical for the proliferation of naïve T cells than for primed T cells 
(Fig. 3.23). This suggests that enhanced stimulation of the naïve T cell pool is 
essential for the augmented total antigen-specific T cell response in α-DC TG 
mice.  
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Fig. 3. 19. IgE/antigen (Ova) complexes are more effectively presented by FcεRI-
expressing DCs to Ova-specific T cells. DCs isolated from α-DC TG (black squares) and WT 
mice (open circles) were cultured with naïve Ova-specific DO11.10 T cells in the presence of 
graded concentrations of haptenized (NP-)Ova (horizontal). Where indicated NP-specific IgE 
(right panel) was added. 3H-thymidine uptake was measured (mean cpm of triplicate cultures + 
s.e.m.; vertical). Unlike in its presence, in the absence of NP-specific IgE (left panel), DCs from 
α-DC TG and WT mice induced the same level of T cell proliferation. Equal IgE-dependent 
naïve T cell activation by FcεRI+ DCs was seen in the BALB/c (responders: DO11.10 T cells) 
and the C57BL/6 background (responders: OTII T cells; data not shown). 
 
 
 
Fig. 3. 20. IgE/FcεRI-dependent amplification of the T cell response results in increased 
TNFα and IL-2 secrection. DCs isolated from α-DC TG (black squares) and WT mice (open 
circles) were cultured with naïve Ova-specific DO11.10 T cells in the presence of graded 
concentrations of haptenized (NP-)Ova (horizontal). Where indicated NP-specific IgE (right) was 
added. TNFα (left panels) and IL-2 (right panels) secretion was measured on day 3. Data 
presented as the mean [pg/ml] ± s.e.m. of triplicate cultures. 
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Fig. 3. 21. IgE-enhanced cell division numbers in naïve T cells stimulated by FcεRI+ DCs. 
DCs from α-DC TG mice were cocultured with CFSE-labelled Ova-specific T cells in the 
presence (squares) or the absence of IgE anti-NP (circles) and graded concentrations of NP-
Ova (horizontal). Mean division numbers of cycling Ova-specific T cells (+ s.e.m., vertical) are 
shown as a function of the concentration of NP-Ova. Mean cell division numbers were 
calculated using the cell numbers contained in the individual peaks of the CFSE fluorescence 
histograms.  
 
 
 
Fig. 3. 22. IgE-enhanced cell cycle entry of naïve T cells stimulated by FcεRI+ DCs. DCs 
from α-DC TG mice were cocultured with CFSE-labelled Ova-specific T cells in the presence 
(squares) or the absence of IgE anti-NP (circles) and graded concentrations of NP-Ova 
(horizontal). The mean percentage (+ s.e.m.) of non-divided cells (i.e., cell which have undiluted 
CFSE fluorescence, vertical) is shown as the function of the concentration of NP-Ova.  
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Fig. 3. 23. IgE and FcεRI-dependent induction of proliferation is functionally more 
relevant for naïve T cells than for primed T cells. DCs from α-DC TG mice were cocultured 
with CFSE-labelled Ova-specific naïve T cells (circles) or in vivo primed T cells (squares) in the 
presence of IgE anti-NP and graded concentrations of NP-Ova (horizontal). The mean 
percentage (+ s.e.m.) of non-divided cells (vertical) is shown as the function of the concentration 
of NP-Ova.  
 
 
To analyze if FcεRI-IgE-antigen crosslinking is sufficient to induce enhanced T 
cell proliferation, we cultured purified DCs with Ova-specific TCR transgenic T 
cells (DO11.10) and added defined concentrations of NP-BSA in presence of 
NP-specific IgE and Ova. DCs from WT and α-DC TG mice induced the same T 
cell response (Fig. 3.24). Thus, BSA-induced FcεRI crosslinking alone is not 
followed by enhanced T cell proliferation. Hence, we conclude that FcεRI-
enhanced antigen uptake but not FcεRI-dependent DC activation is the major 
principle of exacerbated T cell activation in α-DC TG mice.  
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Fig. 3. 24. BSA-induced crosslinking of FcεRI is not sufficient to induce enhanced T cell 
proliferation. DCs isolated from α-DC TG (closed squares) and WT mice (open circles) were 
cultured with naïve Ova-specific Do11.10 T cells in the presence of graded concentration of NP-
BSA (horizontal) in the presence of NP-specific IgE and Ova. 3H-thymdine uptake was 
measured (mean cpm of triplicate cultures ± s.e.m.; vertical) 
 
 
Naïve CD4+ T cells can differentiate into Th1 or Th2 cells, characterized by their 
pattern of cytokine secreted. Whereas Th1 cells predominantly secrete IFN-γ, 
Th2 cells produce IL-4. We asked whether DCs from α-DC TG mice induced 
altered Th differentiation as compared to WT DCs. Thus, we analyzed whether 
the binding of antigen-IgE complexes to FcεRI on DCs influences the 
differentiation of antigen-specific naïve Th cells activated by these cells. For 
this, we used antigen loading conditions to separately analyze FcεRI-dependent 
and fluid phase antigen uptake (Fig. 3.14).  
After antigen uptake in fluid phase, DCs primed naïve Ova-specific T cells to 
differentiate into Th1 cells, whereby IFN-γ dominated the cytokine secretion 
(Fig. 3.25). In contrast, when Ova was targeted to FcεRI on DCs, these cells 
induced IL-4-dominated Th2 differentiation (Fig. 3.25).  
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Fig. 3. 25. Augmented IL-4 and reduced IFN-γ secretion by Ova-specific T cells primed by 
DCs after IgE- and FcεRI-dependent antigen uptake. FcεRI+ DCs loaded with NP-specific IgE 
or unmodified DCs were pulsed with NP-Ova or medium only and co-cultured with naïve OVA-
specific T cells. Mean concentrations (+ s.e.m.) of IL-4 (pg/ml, left vertical axis) and IFN-γ 
(ng/ml; right vertical axis) in culture supernatants as obtained in three independent experiments 
are shown. Experiments were performed in collaboration with E. Fiebiger 
 
 
To see whether this IgE-FcεRI-mediated Th2-skewing has a correlate in vivo, α-
DC TG and WT mice were immunized with Ova intraperitoneally and 
epicutaneously, isolated spleen cells were restimulated in vitro and analyzed for 
Th1 and Th2 cytokine secretion. Following immunization via either anatomic 
route of antigen delivery, we observed strongly amplified Th2 responses in α-
DC TG mice, as evidenced by increased antigen-dependent secretion of IL-4 
and IL-5 as well as by increased Th2:Th1 cytokine ratios (Fig. 3.26a-e). Th2-
dominated cytokine production was not only seen with Ova, but also after the 
immunization with the structurally unrelated birch pollen allergen Betv1, a major 
allergen in humans (Fig. 3.26f) 
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Fig. 3. 26. Augmented Ova-specific in vivo Th2 responses in α-DC TG mice. (a) 
Splenocytes from naïve and Ova-immunized α-DC TG (closed bars) and WT mice (open bars) 
were cultured in the presence of Ova. Pooled splenocytes from three mice per group were 
used. Concentrations of IL-4 (pg/ml, left vertical axis) and IFN-γ (ng/ml; right vertical axis) were 
determined by ELISA. (b) IL-4 /IFN-γ ratios from experiment shown in (a) (c) Th2-skewed 
antigen-specific T cell responses in epicutaneously Ova-sensitized α-DC TG mice. Spleen cells 
from epicutaneously Ova-sensitized or non-sensitized α-DC TG and WT mice were exposed to 
Ova in vitro. IL-4 (black bars, left vertical axis) and IFN-γ concentrations (open bars, right 
vertical axis) in supernatants of splenocytes pooled from three mice per group are shown. (d) 
IL-4 /IFN-γ ratios from experiment shown in (c). (e) IL-5 secretion measured in experiment 
shown in (c). (f) Th2-skewed antigen-specific T cell responses in i.p. birch pollen-sensitized α-
DC TG mice. Spleen cells from i.p. Betv1-sensitized or non-sensitized α-DC TG and WT mice 
were exposed to Betv1 in vitro. Mean concentrations (+ s.e.m.) of IL-4 (vertical) in supernatants 
of splenocytes obtained from 5 mice per group are shown. Experiment was done by N. Duschek 
in collaboration with U. Wiedermann-Schmidt.  
 
 
The in vivo relevance of this enhanced antigen-specific Th2 cytokine secretion 
in α-DC TG mice is further corroborated by the observation of increased serum 
levels of antigen-specific IgE in these mice (Fig. 3.27). Thus, the biological role 
of FcεRI on DCs in vivo is not only to promote T cell expansion both from the 
naïve and memory pool but also to induce and amplify type 2 T cell responses. 
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Fig. 3. 27. Antigen-specific serum IgE is augmented in α-DC TG mice. Elisa-based 
detection of Ova-specific serum IgE in α-DC TG mice (black bars) and WT mice (open bars). 
Mice were immunized i.p. with Ova or were non-immunized (PBS). Mean concentrations of Ova-
specific IgE (+ s.e.m.) obtained with three mice per group are shown.  
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3.4. Exacerbation of allergic late-phase inflammation in α-DC 
TG mice  
 
 
To explore whether the expression of FcεRI on DCs modifies allergic tissue 
inflammation, we induced pulmonary LARs in α-DC TG and WT mice. To 
induce allergic asthma, mice were immunized and sacrificed 72 h after 
challenge with aerosolized antigen.  
 
H&E-stained lung sections evaluated in a blinded fashion (cf. 2.20.3) point 
showed significantly increased inflammatory cell infiltration in lungs of α-DC TG 
mice (Fig 3.28). Lungs of α-DC TG mice, as compared to those of WT mice, 
had denser perivascular and peribronchial inflammatory cuffs frequently 
covering the entire circumferences of those structures (Fig 3.29). Moreover, 
inflammatory cell infiltrates in α-DC TG mice were spread over larger areas of 
lung tissue than in WT controls where infiltrates occurred in a patchy 
distribution. The cellular infiltration tended to extend into the peri- and 
interalveolar space more prominently in α-DC TG than in WT mice (Fig. 3.28 
and 3.29).  
 
Next, we analyzed and quantified the cell subtype composition of lung infiltrates. 
Using FACS analysis, we measured the number of CD45+ leukocytes in lung 
cell suspensions prepared from immunized and non-immunized α-DC TG and 
WT mice exposed to aerosolized Ova 72 h before sacrifice. In this analysis, the 
number of CD45+ hematopoietic cells was significantly increased in allergen-
exposed lungs of α-DC TG mice compared to WT controls (Fig. 3.30), 
supporting the histological observations.  
 
Quantification of cell subtypes within the infiltrate showed that eosinophils were 
present in significantly increased proportions within the CD45+ lung infiltrates of 
α-DC TG mice as compared to those of WT controls (Fig. 3.31). A relative 
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increase in CD11c+ lung-infiltrating cells was also noted in α-DC TG mice (Fig. 
3.31) which becomes more evident taken into account the increase in total 
CD45+ lung cells in these animals. The proportions of other myelomonocytic cell 
subsets and T cells were not significantly different in the lungs of α-DC TG and 
WT mice. Hence, we conclude that the expression of FcεRI on DCs enhances 
both the magnitude and the eosinophil and, possibly, DC component of 
inflammatory cell infiltration in allergic pulmonary late-phase reactions. 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 28. Increased pulmonary infiltration in α-DC TG mice. The spread of the infiltrate (left 
panel), the extent of infiltration (middle panel) and its extension into the peri- and intraalveolar 
space (right panel) were quantified, in a blinded fashion, by microscopic scoring of H&E-stained 
lung sections from i.p. Betv1-immunized and allergen aerosol-challenged α-DC TG (black bars) 
and WT mice (open bars). Results are presented as mean scores (+ s.e.m.) as obtained with 
lungs of 7 mice per group. **, p<0.01. Experiment was performed in collaboration with A. Rot.  
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Fig. 3. 29. Representative examples of inflammatory lung pathology in α-DC TG and WT 
mice. H&E-stained lung sections from WT mice show patchy inflammatory infiltrates that are 
demarcated from bronchi/bronchioli (upper left panel). In α-DC TG lungs, inflammatory infiltrates 
form peribrochial cuffs frequently covering the entire circumference of these structures (upper 
right panel). Infiltrates are not demarcated from but intimately associated with 
bronchi/bronchioli. This subepithelial, peribronchial area is the very location of FcεRI+ DC 
accumulation in inflamed α-DC TG lungs (see text). The inflammatory infiltrates in α-DC TG 
lungs are formed by mononuclear cells and contain a prominent proportion of eosinophils both 
in parenchymal (lower left panel) and alveolar regions (lower right panel); b, 
bronchus/bronchiolus. Experiment was performed in collaboration with A. Rot.  
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Fig. 3. 30. Quantification of allergen-induced lung infiltration with CD45+ hematopoietic 
cells. Naïve and i.p. Ova-immunized α-DC TG (black bars) and WT mice (open bars) were 
exposed to aerosolized Ova. The number of CD45+ cells contained in lung single cell 
suspensions was measured by flow cytometry and normalized to the content of CD45+ cells in 
lungs of non-immunized mice. The mean (+s.e.m.) of data obtained with three mice per group is 
shown.  
 
 
 
 
 
 
 
 
Fig. 3. 31. Increased pulmonary infiltration with CD11c+ hematopoietic cells and 
eosinophils in α-DC TG mice. Subtyping analysis of the hematopoietic inflammatory lung 
infiltrates in Ova-sensitized and Ova-challenged α-DC TG (black bars) and WT mice (open 
bars). The mean percentual contribution (+ s.e.m.) of F4/80+ macrophages, CD11b+ and 
CD11c+ myeloid cells, eosinophils, and T cells to the CD45+ lung infiltrate as determined in 
three mice per group is shown. *, p<0.05; **, p<0.01.  
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3.5. Airway-associated FcεRI+ DCs accumulate in allergic 
lung inflammation 
 
 
The observation of larger numbers of CD11c+ cells in lungs of α-DC TG mice 
than of WT mice led us to analyze the nature, localization and pulmonary 
recruitment of transgene-expressing lung DCs in greater detail.  
Thus, we examined eGFP-expressing cells in lungs harvested from immunized 
and aerosol-challenged mice. Only few eGFP+CD11c+ DCs were present in 
single cell suspensions prepared from lungs of naïve, of Ova-challenged or of 
Ova-immunized but only mock-challenged α-DC TG mice (Fig. 3.32, 3.33).  
In contrast, the lungs of Ova-sensitized and Ova-challenged mice contained a 
large population of eGFP+CD11c+ DCs (Fig. 3.33 and 3.35). Analyzing this large 
eGFP+ population, we showed that these cells express FcεRI. Isolated 
eGFP+CD11c+ lung cells expressed FcεRI and strongly stimulated Ova-specific 
T cell proliferation (Fig. 3.33, 3.34). eGFP-CD11c+ lung cells, in contrast, did not 
express FcεRI and were poor stimulators of T cell proliferation (Fig. 3.33, 3.34). 
Thus, eGFP expression in α-DC TG mice is a marker of lung DCs since eGFP 
expression visualizes the functionally competent FcεRI+CD11c+ lung DC 
population in these animals. Furthermore, eGFP+ cells showed only low-
autofluorescence thus excluding transgene expression in macrophages which 
are characterized by high level autofluorescence in both WT and α-DC TG mice 
(98, 99, Fig. 3.37). 
 
In mock-challenged α-DC TG mice, the eGFP+ DCs localized in close proximity 
to bronchioli but did not infiltrate the lung parenchyma (Fig. 3.34). In Ova-
sensitized and Ova-challenged mice, eGFP+ DCs infiltrated in large numbers 
bronchioli and small bronchi as well as the alveolar lung parenchyma (Fig. 
3.35). Closer inspection of the airway-associated DCs revealed that their cell 
body localized just beneath the bronchial epithelium and that these cells, from 
their apical aspect, project a discontinuous network of dendrite-like cell 
protrusions into the basal lamina of the small airways (Fig. 3.34). In contrast to 
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sensitized and challenged mice, mice that were only sensitized or were only 
exposed to aerosolized antigen did not show any alteration of lung DC number 
or localization (Fig. 3.31, 3.32, 3.34). Thus, the recruitment of FcεRI+ DCs to the 
lung is linked to the elicitation of an antigen-specific immune response in situ.  
 
 
 
 
 
 
 
 
 
 
Fig. 3. 32. No alteration of lung DC number in naïve or only aerosol-challenged mice. 
eGFP expression of CD45+CD11c+ lung cells from naïve α-DC TG mice (left histogram) and 
naïve α-DC TG mice after inhalation of aerosolized Ova (right histogram) Vertical lines indicate 
the upper cut-off of autofluorescence of CD45+CD11c+ lung cells from WT mice. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 33. The number of eGFP+CD11c+ cells is greatly increased in allergic lung 
inflammation. eGFP expression of CD45+CD11c+ lung cells from i.p. Ova-immunized α-DC TG 
mice after inhalation of aerosolized Ova (right histogram, left panel) or PBS only (left histogram, 
left panel). Vertical lines indicate the upper cut-off of autofluorescence of CD45+CD11c+ lung 
cells from WT mice. Gated eGFP+ (P2, blue), but not eGFP- (P1; red) CD11c+ lung cells express 
human FcεRIα (left histogram, right panel). Both, eGFP+ and eGFP-CD11c+ lung cells lack 
CD11b (right histogram, right panel). 
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Fig. 3. 34. In contrast to their eGFP- counterparts, eGFP+CD11c+ lung cells are strong 
stimulators of Ova-specific T cell proliferation. eGFP+CD11c+ (full circles) and eGFP-
CD11c+ lung cells (full triangles) and, for comparison, eGFP+CD11c+ splenic DCs (open circles) 
were co-cultured with Ova-specific T cells (T cells alone: open diamonds) in the presence of 
graded concentrations of Ova (horizontal). 3H-thymidine uptake of triplicate cultures was 
measured (mean cpm + s.e.m.; vertical). 
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Fig. 3. 35. eGFP+ DCs accumulate in Ova-dependent allergic lung inflammation. Lung 
sections from non-immunized α-DC TG mice (upper right panel: exposed to aerosolized Ova 
only (PBS/Ova); upper left panel: PBS inhalation only (PBS/PBS)) and Ova-immunized and Ova 
aerosol-challenged α-DC TG mice (Ova/Ova; lower left panel) were analyzed by confocal laser 
scanning microscopy. Higher magnification shows eGFP+ DCs closely associated with bronchi 
and projecting dendrites into the bronchial basal lamina (arrowheads in lower right panel). 
Fluorescence light emission of 505-550 nm was recorded. b, bronchus/bronchiolus; v, blood 
vessel; e, bronchial epithelium. 
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Fig. 3. 36 . Lung DCs but not macrophages (MΦs) express eGFP. Lung sections from Ova-
immunized and Ova-challenged α-DC TG mice (left panels) were analyzed by confocal 
microscopy. Fluorescence light emission of 505-550 nm (green, upper left panel) and of 560-
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615 (red, middle right panel) was recorded. Due to their broad autofluorescence, Mφs show 
equal light emission in both wavelength ranges. DCs, in contrast, emit light in the eGFP 
emission spectrum of 505-550 nm only (arrowheads). Lower left panel: merged image of the 
upper panels. As shown in the right panels, lung MΦs of WT mice display green (upper right 
panel) and red (middle right panel) autofluorescence equivalent to MΦs of α-DC TG mice. 
Lower right panel: merged image of the upper panels. In contrast to α-DC TG mice, cells with 
green but not red fluorescence cannot be discerned in WT mice. Arrows in the merged image 
(lower right panel) denote autofluorescent MΦs.  
 
 
Lung recruitment of eGFP+ DCs was also analyzed in IgE-/- α-DC TG mice. 
Expectedly, in IgE-/- α-DC mice no Ova-specific IgE was detectable after Ova 
immunization and lung challenge (Fig. 3.36). 
In IgE-/- α-DC TG mice, the lung recruitment of eGFP+ DCs was reduced (Fig. 
3.37). Thus, the in vivo interaction of IgE with FcεRI on DCs also contributes to 
DC accumulation in the allergen-exposed lungs. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 37. Antigen-specific serum IgE is not detectable in IgE-/- α-DC TG mice. Ova-specific 
serum IgE in Ova-immunized or non-immunized (PBS) α-DC TG mice (closed bars) and IgE-/- α-
DC TG mice (grey bars). Results are presented as mean level of Ova-specific IgE relative to the 
PBS-treated control group as obtained with three mice per group.  
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Fig. 3. 38. Inflammation-associated recruitment of FcεRI+ DCs depends, in part, on IgE. 
The percentage of eGFP+ DCs among all CD45+ lung cells was determined by flow cytometry in 
naïve or Ova-treated α-DC TG (closed bars) and IgE-/- α-DC TG mice (gray bars). Results are 
presented as mean % (+s.e.m.; vertical) as obtained with three mice per group 
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3.6. FcεRI on DCs instigates IgE-dependent pulmonary Th2 
activation and eosinophil chemoattraction to the lung  
 
 
To see whether enhanced T cell activation indeed occurs in lungs of α-DC TG 
mice as compared to WT controls we performed adoptive in vivo transfer of 
CFSE-labelled Ova-specific T cells into Ova-immunized α-DC TG and WT 
control mice. Injected T cells homed to lung and the spleen in about the same 
frequency (Fig. 3.39). 
By analyzing the CFSE-dependent fluorescence of Ova-specific T cells in lungs 
exposed to aerosolized Ova, we were able to monitor antigen-dependent T cell 
proliferation in situ (Fig. 3.40).  
As shown in Fig. 3.41, Ova-specific lung T cells underwent, on average, 67% 
more cell divisions in α-DC TG mice than in WT controls (mean divisions in α-
DC TG: 5.5; mean divisions in WT: 3.3). Thus, enhanced T cell activation in situ 
by FcεRI+ lung DCs can contribute to the observed increased allergic late-
phase-associated inflammatory cell infiltration in the lungs of α-DC TG mice. 
 
 
 
 
 
 
 
 
Fig. 3. 39. T cells home to the lung and the spleen at about the same frequency. 
Measurement of CFSE fluorescence of Ova-specific T cells in the lung (left panel) and spleen 
(right panel). CFSE-labelled DO11.10 T cells were transferred in Ova-immunized α-DC TG 
mice. From single cell lung suspensions, CD45+CD3+CD4+ T cells were gated and DO11.10 T 
cells identified by their reactivity with the clonotype TCR-specific mAb KJI-26 (vertical). DO11.10 
T cells recovered from lungs of naïve control mice were used to define the CFSE fluorescence 
intensity gate of non-divided cells. 
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Fig. 3. 40. Activation of T cells occurs after allergen exposure. Measurement of in vivo 
proliferation of Ova-specific T cells in the lung (left panel) and the spleen (right panel). CFSE-
labelled DO11.10 T cells were transferred in Ova-immunized α-DC TG mice and mice were 
exposed to aerosolized Ova. From single cell lung suspensions, CD45+CD3+CD4+ T cells were 
gated and DO11.10 T cells identified by their reactivity with the clonotype TCR-specific mAb 
KJI-26 (vertical). DO11.10 T cells recovered from lungs and spleens of naïve control mice were 
used to define the CFSE fluorescence intensity gate of non-divided cells. 
 
 
 
 
 
 
 
 
 
Fig. 3. 41. Measurement of in vivo proliferation of Ova-specific lung T cells. CFSE-labelled 
DO11.10 T cells were transferred in Ova-immunized WT (left panel) and α-DC TG mice (right 
panel) and mice were exposed to aerosolized Ova. From single cell lung suspensions, 
CD45+CD3+CD4+ lung T cells were gated and DO11.10 T cells identified by their reactivity with 
the clonotype TCR-specific mAb KJI-26 (vertical). DO11.10 T cells recovered from lungs of 
naïve control mice were used to define the CFSE fluorescence intensity gate of non-divided 
cells (gate 0). CFSE dilution by a factor of two per cell division allows to track up to 8 cell 
divisions in Ova-specific lung T cells (gates 1-8). Mean cell division numbers are indicated. 
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Next we analyzed whether the enhanced lung T cell response in α-DC TG mice 
was Th2 dominated or not. As shown in Fig. 3.42, antigen-dependent IL-4 
mRNA production was upregulated in lungs from immunized and Ova-
challenged α-DC TG mice as compared to those from immunized and 
challenged WT mice. In immunized and challenged IgE-/- α-DC TG mice the 
increase in IL-4 mRNA was much less evident than in α-DC TG mice, 
particularly when considering the relative increase in CD3 mRNA in the IgE-
deficient animals (Fig. 3.42). Thus, we conclude that IgE binding to FcεRI+ lung 
DCs contributes to a strong allergen-specific Th2 response in the lung. 
 
Eosinophils are not present in non-inflamed peripheral tissues. Thus eosinophils 
must be actively recruited to the site of allergic inflammation, the consequence 
of direct or indirect effects of Th2 cell activation in situ (121).  
Among the Th2-related candidates of eosinophil chemoattractants, we found 
eotaxin upregulated in lungs of immunized and challenged α-DC TG mice, while 
RANTES was expressed equally in α-DC TG and WT mice (Fig. 3.42). The 
upregulated expression of eotaxin but not RANTES expression depended on 
IgE in lungs of α-DC TG mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 42. IL-4 and eotaxin mRNA production is upregulated in lungs of α-DC transgenic 
mice during allergic inflammation. Quantitative real-time PCR analysis of CD3, IL-4, eotaxin, 
and RANTES mRNA expression in lung cells of naïve and Ova-immunized and -challenged WT 
(open bars), α-DC TG (black bars), and IgE-/- α-DC TG mice (grey bars). Expression values 
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obtained were normalized to housekeeping gene expression and mean values (+ s.e.m., 
vertical) obtained with at least 3 mice per group are given. **, p<0.01. Experiment was 
performed in collaboration with U. Wiedermann-Schmidt. 
 
 
Since α-DC TG mice mount an enhanced systemic Th2 cell response that 
depends on the presence of antigen-specific IgE, we asked whether the 
enhanced eosinophil recruitment in these mice is equally IgE-dependent. Thus, 
we compared eosinophil recruitment to antigen-exposed lungs of immunized 
WT,  α-DC TG mice and α-DC TG mice with genetic ablation of IgE.  
As shown in Fig. 3.43, the increased eosinophil recruitment to lungs of α-DC TG 
mice is completely lost in the IgE-/- α-DC TG background. Thus, IgE deficiency 
abolishes specifically the eosinophil recruitment-enhancing effect of DC-
expressed FcεRI and leaves antigen-dependent eosinophil recruitment 
operative at the level seen in WT animals. Collectively, IgE interaction with 
FcεRI on lung DCs results in pulmonary Th2 activation, overproduction of 
eosinophil chemoattractants and IgE-dependent eosinophil recruitment what is 
not seen in WT animals. 
 
 
As reported previously, we found that IgE deficiency does not alter the 
magnitude of lung eosinophilia in mice that do not express FcεRI on DCs but 
express FcεRI on their mast cells (124, Fig. 3.44). Thus, IgE-dependent lung 
eosinophil recruitment requires the expression of FcεRI on DCs but not FcεRI 
expression on mast cells.  
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Fig. 3. 43. IgE-dependent eosinophil lung infiltration in α-DC TG mice but not in WT mice. 
Lung eosinophils in naïve or Ova-immunized WT (open bars), α-DC TG (black bars), and IgE-/- 
α-DC TG mice (gray bars), after either PBS (-) or Ova (+) inhalation, were counted by flow 
cytometry. Mean eosinophil counts (+s.e.m.) relative to the counts in the PBS only-treated 
group as obtained with lungs from three mice per group are shown. **, p<0.01.  
 
 
 
Fig. 3. 44. IgE-deficiency in mice not expressing FcεRI on DCs does not negatively affect 
eosinophil lung recruitment. Lung eosinophils in Ova-immunized and Ova-challenged WT 
(IgE+/+, open bar) and IgE-/- mice (gray bar) were counted by flow cytometry. Mean eosinophil 
counts (+ s.e.m.) relative to the counts in WT mice as obtained with lungs from three mice per 
group are shown. 
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The enforced recruitment of tissue-destructing and remodelling eosinophils to 
lungs of α-DC TG may be solely due to facilitated Th2 cell activation in situ by 
IgE-loaded FcεRI+ DCs accumulating in the allergen-exposed tissue. This is 
supported by the strict dependence of FcεRI+ DC-mediated eosinophil 
recruitment on antigen priming and challenge. Besides, the mutually non-
exclusive possibility exists that antigen/IgE binding to FcεRI+ tissue DCs, by 
itself, leads to eosinophil attraction in a rather T cell-independent fashion. To 
test this in vivo, human FcεRIα-specific mAbs with established FcεRI triggering 
capacity were injected into α-DC TG and control mice, both on the IgE-deficient 
background to retain FcεRI unoccupied. 
 
As shown in Fig. 3.45, the systemic and selective engagement of DC-expressed 
FcεRI led to enhanced eosinophil migration to the spleen. We also noted 
increased numbers of eosinophils in the lungs of mAb-treated α-DC TG mice. 
The magnitude if this response was, however, somewhat smaller, possibly due 
to competition of the various organs for eosinophil recruitment in the setting of 
systemic FcεRI activation. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 45. In vivo activation of FcεRI increases eosinophil recruitment independently of 
IgE and antigen. IgE-/- and IgE-/- α-DC TG mice injected with control antibody (open bars) or 
anti-huFcεRIα (15-1; black bars) antibody. Spleen (left) and lung (right) eosinophils in IgE-/- and 
IgE-/- α-DC TG were counted by flow cytometry. Mean eosinophil counts (+ s.e.m.) relative to 
the counts in the PBS only-treated group as obtained with lungs from three mice per group are 
shown **, p<0.01. 
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4. Discussion 
 
 
The in vivo role of FcεRI expressed on mast cells in allergy is well known. 
Crosslinking of FcεRI by IgE-allergen-complexes leads to mast cell activation 
and subsequent release of preformed mediators which may result in an 
anaphylactic response in the worst case scenario (1, 7). The in vivo role of 
FcεRI expressed on mast cells was further demonstrated in studies using mice 
deficient in FcεRI or IgE (124).  
Unlike in mice, in humans, FcεRI is expressed not only on mast cells and 
basophils but also on antigen-presenting DCs (10, 12, 13). However, the in vivo 
relevance of DC-expressed FcεRI and its contribution in IgE-dependent 
induction of allergic inflammation remained unknown. This is mainly due to the 
lack of a suitable mouse model to study the role of DC-expressed FcεRI in 
allergic reactions. To overcome this limitation, our laboratory generated α-DC 
TG that display a “humanized” FcεRI expression pattern.  
α-DC TG mice express on their DCs FcεRI composed of a human FcεRI α-
chain and the murine FcεRIγ-chain-dimer, which is expressed endogenously in 
murine DCs. Thus, α-DC TG mice, as humans, express FcεRI on DCs as trimer 
lacking the β-chain. In vivo, expression of huFcεRI is restricted to DCs. Other 
cell types like T cells, B cells and macrophages do not express 
huFcεRIα/muFcεRIγ2 complexes. The restriction of huFcεRI-expression on DCs 
is the result of a constitutively active DC-specific promoter and the requirement 
of endogenous FcεRI γ-chain for surface expression of a functional FcεRI (27). 
As in humans, FcεRI is predominantly expressed on CD4+ myeloid DCs and 
less on CD8+ lymphoid DCs and plasmacytoid DCs. In addition, DCs from 
lymphoid organs like spleen and lymph nodes as well as from non-lymphoid 
organs like the lung express FcεRI. Functionality of FcεRI expressed on DCs 
was confirmed by its ability to bind both murine and human IgE in vivo and in 
vitro. Furthermore, we demonstrated that DCs from α-DC TG mice but not from 
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WT mice had the capacity of FcεRI-mediated and IgE-dependent antigen 
uptake und presentation.  
 
The late-phase of allergic reaction (LAR) is characterized by chemokine- and 
cytokine-induced recruitment of leukocytes like DCs, T lymphocytes and 
eosinophils to sites of allergen exposure (1). LARs rather than the early-phase 
of allergic reaction (EAR) contribute to the morbidity and mortality in asthma. 
Eosinophils are a characteristic hallmark of the pathologic infiltrative process of 
asthma and are regarded as key effector cells of LARs. Eosinophils are bone 
marrow-derived granulocytes normally circulating in the blood. Th2 cell-released 
cytokines induce eosinophil maturation and their recruitment to LAR 
inflammatory sites (1, 120). Interestingly, Mehlhop et al. demonstrated that 
eosinophilic inflammation occurs even in IgE-deficient mice (124). The 
pulmonary histology was identical in IgE-deficient and WT mice concluding that 
IgE and, thus, FcεRI expressed on mast cells is not involved in the pathway of 
eosinophil recruitment to lungs of allergic WT mice. Furthermore, Takeda et al. 
showed in mast cell-deficient mice that even mast cells are not required for the 
development of eosinophilic inflammation (123). The fact that IgE, mast cells 
and, thus, mast cell-expressed FcεRI are not mandatory for eosinophil 
recruitment in the course of LARs permits a functional separation of the early 
and late-phase of allergic reaction. In human asthma, in contrast to mice, there 
is a correlation between antigen-specific IgE levels and eosinophil recruitment. 
As the consequence, increased antigen-specific IgE has a significant amplifying 
effect on the severity of the LAR in human asthma. This understanding 
originates from anti-IgE treatment studies in human asthmatics. For instance, 
Fahy et al. demonstrated that treatment with a humanized murine monoclonal 
antibody directed to the FcεRI-binding domain of IgE decreases serum IgE and 
drastically reduces the late-phase allergic response (125). Hence, besides the 
well-known role of IgE on mast cells, there has to be an additional function of 
IgE for the development of LARs in humans.  
We compared eosinophil lung recruitment in response to aerosolized antigen in 
α-DC TG and WT mice. It must be pointed out that the only difference between 
Mitterhumer Eva              Discussion 
 
 131 
α-DC TG and WT mice is the expression of FcεRI on DCs and not on mast cells 
and basophils. In α-DC TG mice, we observed significantly increased and IgE-
dependent LAR-associated eosinophil lung recruitment. Thus, we concluded 
that DCs through their in vivo expression of FcεRI are capable to increase lung 
eosinophilia in an IgE-dependent fashion.  
 
In our studies, we could show that FcεRI-expressed on DCs can augment IgE-
dependently antigen-specific T cell responses. This is due to a more efficient 
allergen-uptake, processing and allergen-derived peptide presentation to T cells 
mediated by FcεRI and IgE. Thus, targeting of allergen-IgE complexes to FcεRI 
expressed on DCs results in an amplified allergen-specific T cell response. 
Noteworthy, DCs in α-DC TG mice and humans express FcεRI. This fact 
corroborates the central role of IgE rather than of IgG in the modulation of 
antigen thresholds for DC-dependent T cell activation. Interestingly, our results 
also show that the proliferation-promoting function of IgE was stronger for naïve 
than for primed T cells. Thus, FcεRI-IgE mediated antigen-presentation may 
amplify T cell activation in vivo also by engaging the hitherto non-activated 
naïve T cell pool to participate in the allergic reaction.  
In summary, FcεRI-facilitated antigen-presentation by DCs in vivo may be 
crucial for the expansion of memory T cells but may also boost the priming of 
naïve T cells which possibly will contribute to the diversity of the T cells 
response in terms of affinity and repertoire of recognized allergen peptides. 
 
In α-DC TG mice, we found an augmented Th2 cell response not only in 
lymphoid organs, but also in non-lymphoid organs, such as the lung. After 
allergen-exposure, lung T cells expressing clonotypic T cell receptors 
underwent more cell division in sensitized α-DC TG mice than in WT controls. 
Furthermore, the absolute number of T cells was increased in lungs of allergen-
sensitized and challenged α-DC TG mice compared to those from naïve α-DC 
TG mice which becomes evident taken into account the increase in total CD45+ 
lung cells in these animals. IgE-FcεRI-dependent T cell activation by DCs also 
induced Th2-cell polarization in vivo. Comparing the Th differentiation following 
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FcεRI-mediated and fluid-phase antigen uptake in DCs, we observed Th1 
polarization in the case of conventional fluid-phase antigen uptake. In contrast, 
DCs which had taken up IgE-antigen complexes via FcεRI induced Th2 cell 
differentiation. Thus, it appears likely, that IgE-FcεRI-mediated antigen uptake 
results in FcεRI signaling eliciting a Th2-inducing program in DCs. Recent 
studies show such an enhanced Th2 response for rare basophils (129, 130, 
131). Perrigoue et al. demonstrated a MHC class II-dependent activation of 
CD4+ T cells by basophils in helminth infection (130). Yoshimoto et al. showed 
that basophils loaded with IgE-antigen complexes acts as potent antigen-
presenting cell in mice infected with Strongyloides venezuelensis (129) and 
Sokol et al. demonstrated that basophils function as APCs during a papain 
induced Th2 response (131). Thus, basophils and DCs play a pivotal role in the 
induction of Th2 responses. Basophils are normally located in the bone marrow 
and the blood and migrate rarely, and if so late into the inflamed tissues. In 
contrast to rare basophils, DCs are present in higher numbers in even non-
inflamed lymphoid and non-lymphoid organs and further accumulate at sites of 
inflammation. Due to the preferential occurrence of DCs in terms of tissue 
location and quantity, we speculate, that FcεRI+ DCs play the crucial role in the 
induction of Th2 responses, whereas basophils, which appear rarely and late in 
the course of allergic inflammation, may amplify DC-induced Th2 responses.  
 
In our study, the in vivo relevance of this FcεRI-dependent Th2 promotion is 
directly shown by increased Th2 cytokine secretion in allergen stimulated 
splenocytes and in lungs from α-DC TG compared to WT mice. It is important to 
note that amplified IL-4 secretion in α-DC TG mice occurs independently of the 
route of sensitization, as similar results were obtained after intraperitoneal and 
epicutaneous sensitization. This is of particular medical importance since 
epicutaneous sensitization to antigen may be a key factor for the development 
of asthma-associated allergic disorders, such as atopic dermatitis (132).  
 
Our studies suggest a central role of DCs and FcεRI on DCs in orchestrating 
inflammatory reactions resulting in an IgE-dependent amplification of lung 
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LARs. Sertl et al. was the first to illustrate the presence of DCs within the lungs 
of humans and mice (97). Their study demonstrated the presence of DCs within 
the airway epithelium, lung parenchyma and visceral pleura. Later studies from 
Tunon-De-Lara et al. demonstrated the presence of DCs in both normal and 
asthmatic human lungs within the bronchial epithelium and in the subepithelial 
tissue. Furthermore, these studies showed a significant increase of DCs in 
lungs of asthmatics compared to normal lungs. The majority of these lung DCs 
expressed FcεRI and displayed cell-bound IgE (102). α-DC TG mice fully 
recapitulate this DC and FcεRI representation seen in human lungs. In naïve α-
DC TG mice, only few eGFP+ cells were detected. These cells localize close to 
bronchioli but do not infiltrate the lung parenchyma. Aerosol-challenge with 
antigen in already sensitized α-DC TG mice lead to the increased recruitment of 
FcεRI+ DCs resembling the situation in human asthmatic lungs. These newly 
recruited transgene-expressing DCs are found within and just beneath the 
bronchial epithelium as well as in the lung parenchyma. Their localization just 
beneath the bronchial epithelium also allows DCs extend their dendrites 
beneath and between epithelial cells. Our microscopic analyses indeed show 
that FcεRI+ DCs extend elongated dendrites towards the alveolar lumen, most 
likely to probe for IgE-reactive inhaled allergen.  
Our results allow the speculation that allergen binding by FcεRI-bearing DCs 
will drastically lower the critical antigen threshold required for T cell activation in 
the lung and the draining lymph nodes. This is also illustrated by the 
observation that IgE-dependent antigen presentation leads to an increased Th2-
cell activation in the lungs of α-DC TG mice compared to WT controls. This 
initial event of IgE-dependent lung Th2 cell activation by FcεRI+ DCs may 
provide the essential chemotactic signals for eosinophil lung recruitment and 
the function of accumulation of FcεRI+ DCs which is, in part, also dependent on 
IgE-FcεRI interactions. Corroborating these novel observations, Djukanović et 
al. demonstrated in anti-IgE-treated (omalizumab) asthmatic patients a strong 
decrease in IgE+ and FcεRI+ cells in bronchial biopsy specimens (133).  
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Eosinophils are not present in non-inflamed peripheral tissues but recruited at 
the site of inflammation. Eosinophil recruitment to the lung occurs in response 
to the in situ activation of antigen-specific Th2 cells and is effectuated by the 
Th2 cytokine-induced production of eosinophil chemoattractants. Robinson et 
al. demonstrated a close correlation of eosinophil counts and activated CD4+ T 
cells producing IL-4 and IL-5 mRNA in human asthma (121). They concluded 
that cytokines produced by activated Th2 cells contribute to eosinophil 
recruitment and thus delayed-type lung inflammation. Our results also show this 
correlation of eosinophil counts and increased IL-4 and eotaxin. Furthermore, 
we provide an additional possibility of eosinophil recruitment. We have evidence 
that transgene-expressing DCs can recruit eosinophils to the lung in a T cell 
independent way by direct triggering of FcεRI. In α-DC TG mice, in vivo 
activation of FcεRI on DCs through systemic presence of human FcεRI 
agonistic mAbs enhance tissue eosinophilia. Thus, we conclude that FcεRI+ 
DCs can exert at least three IgE-dependent synergistic activities for eosinophil 
recruitment: (i) augmentation of the systemic Th2 pool size, (ii) enhancement of 
T cell activation in the allergen-exposed organ and (iii) immediate attraction of 
inflammatory cells after triggering of their FcεRI by IgE-allergen complexes (Fig. 
4.1). 
 
Steroids are the first class therapy for asthma since they are still the only drug 
preventing mortality in human asthma (134). Inhaled corticosteroids reduce 
eosinophils LARs and its consequence, tissue damage, an irreversible lung 
function impairment. Besides the clinically benefit of corticosteroid treatment, 
this therapy has various adverse effects particularly during prolonged and high-
dose application. Our finding that DCs in the lung and their trimeric FcεRI 
participate directly in the induction and severity of pulmonary LARs provides a 
new target for the development of novel therapies against allergic inflammation.  
For this pharmacological intervention, efficacious and persistent blockade of 
DC-expressed FcεRI is likely necessary to present the aggravation of LAR-
associated tissue inflammation after allergen exposure as well as the IgE-
FcεRI-dependent Th2 cell skewing. The use of our α-DC TG mouse model 
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which recapitulates the human situation of atopic inflammation in a fashion 
superior to WT mice will allow further investigations on novel therapies targeting 
FcεRI. 
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